日本臨牀　77/増刊2　心不全（第2版）下

出版社： 日本臨牀社
発行日： 2019-05-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 心不全（第2版）下
電子書籍版： 2019-05-31 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 特集　心不全（第2版）下―最新の基礎・臨床研究の進歩―

    ◇序　文

    XIX．看護・管理・支援
    　１．心不全の包括的疾病管理
    　２．心不全患者のセルフケア支援
    　３．心不全患者・家族の精神支援
    　４．LVAD患者の管理、支援
    　５．心不全患者の在宅管理
    　６．心不全管理における訪問看護師の役割
    　７．心不全の外来管理
    　８．心不全における地域連携
    　９．心不全と認知機能障害
    　10．心不全における周術期看護
    　11．心不全における呼吸管理
    　12．心不全における妊娠管理
    　13．心不全における服薬管理

    XX．心不全の併存症―病態・治療―
    　1．不整脈
    　　（1）心房細動
    　　　　1）レートコントロール
    　　　　2）リズムコントロール（カテーテルアブレーションを含めて）
    　　　　3）抗凝固療法
    　　　　4）左心耳閉鎖デバイス
    　　（2）心室不整脈
    　　　　1）薬物治療
    　　　　2）心室性不整脈に対するカテーテルアブレーション
    　　（3）徐脈性不整脈
    　　（4）心不全に用いられる抗不整脈薬
    　　（5）心不全に伴う不整脈を理解するために必要な心臓解剖
    　2．冠動脈疾患
    　3．弁膜症
    　4．高血圧
    　5．糖尿病
    　6．脂質異常症
    　7．CKD
    　8．心不全における高尿酸血症の意義
    　9．COPD・喘息
    　10．貧血
    　11．肺高血圧
    　　（1）肺高血圧
    　　（2）慢性血栓塞栓性肺高血圧症に対する肺動脈形成術
    　12．睡眠呼吸障害
    　13．うつ・不安
    　14．心不全と脳卒中
    　15．感染症

    XXI．心不全の原因疾患(基礎疾患)―病態，発症機序(心不全)，治療―
    　1．虚血性心疾患
    　　（1）虚血性心不全
    　　（2）冠血行再建の役割
    　2．心筋疾患
    　　（1）拡張型心筋症
    　　（2）肥大型心筋症
    　　（3）特発性拘束型心筋症
    　　（4）不整脈原性右室心筋症
    　　（5）心筋緻密化障害
    　　（6）たこつぼ症候群
    　　（7）頻脈誘発性心筋症
    　　（8）心臓サルコイドーシス
    　　（9）心アミロイドーシス
    　　（10）筋ジストロフィー
    　　（11）Fabry病
    　　（12）糖尿病性心筋障害(糖尿病性心筋症)
    　　（13）薬剤性心筋症
    　　（14）周産期心筋症
    　　（15）ミトコンドリア病
    　　（16）ヘモクロマトーシス・鉄過剰症に伴う心筋症
    　　（17）アルコール性心筋症
    　　（18）甲状腺機能異常による心筋症
    　　（19）脚気心
    　3．心膜疾患
    　　（１）心タンポナーデ
    　　（２）収縮性心膜炎
    　　（３）尿毒症
    　4．弁膜症
    　　（1）大動脈弁狭窄症の病態および治療について
    　　（2）大動脈弁閉鎖不全症の病態、発症機序（心不全）、治療
    　　（3）僧帽弁狭窄症の診断と治療
    　　（4）僧帽弁閉鎖不全症
    　　（5）人工弁不全
    　5．心筋炎
    　　（1）感染性心筋炎・非感染性心筋炎
    　　（2）劇症型心筋炎
    　6．先天性心疾患
    　　（1）小児先天性心疾患
    　　（2）成人先天性心疾患
    　7．高血圧症
    　　（1）高血圧性心疾患
    　　（2）腎血管性高血圧
    　　（3）腎実質性高血圧
    　　（4）心不全の原疾患-アルドステロン症
    　　（5）褐色細胞腫における心不全

    XXII．その他病態・年齢層の心不全の臨床的事項
    　1．胎児心不全
    　2．未熟児・新生児心不全(心内奇形を伴わない)
    　3．高齢者心不全
    　4．妊娠時の心不全
    　5．心不全の性差

    XXIII．特　論
    　1．オンライン診療の出現と心不全管理への応用
    　2．地域で取り組む心不全診療
    　3．NKT細胞活性化による慢性炎症制御
    　4．体外衝撃波療法
    　5．和温療法
    　6．心不全治療としての迷走神経刺激/Vagal nerve stimulationの可能性
    　7．ICTによる疾病管理
    　8．植込型VAD患者の遠隔診療
    　9．災害時における心不全管理
    　10．心血管シミュレーション
    　11．睡眠・サーカディアンリズムと心不全
    　12．経カテーテル的心房中隔シャント作成術
    　13．慢性心不全に対する代替・補完療法（漢方薬）
    　14．補助循環用ポンプカテーテル：インペラ（IMPELLA）
    　15．心不全の遺伝子治療の現状と今後の展望
    　16．CIBIS-J試験
    　17．J-SHIFT試験

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

XIX 看護・管理・支援

P.15 掲載の参考文献
1) Krumholz HM, et al : A taxonomy for disease management : A scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation 114 : 1432-1445, 2006.
PubMed
2) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2018年12月閲覧)
 
3) 菊地和則 : 多職種チームの3つのモデル-チーム研究のための基本的概念整理-. 社会福祉学 39 : 273-290, 1999.
 
4) Rogers JG, et al : Palliative Care in Heart Failure : The PAL-HF Randomized, Controlled Clinical Trial. J Am Coll Cardiol 70 : 331-341, 2017.
PubMed
5) Rich MW, et al : Prevention of readmission in elderly patients with congestive heart failure : results of a prospective, randomized pilot study. J Gen Intern Med 8 : 585-590, 1993.
PubMed
6) Roccaforte R, et al : Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 7 : 1133-1144, 2005.
PubMed
7) Tsuchihashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-a study in Fukuoka, Japan. Jpn Circ J 64 : 953-959, 2000.
PubMed
8) 林亜希子, ほか : 心不全患者の服薬行動に関する研究の動向と課題 : Systematic Reviewからの考察. 心臓 50 : 152-163, 201&
 
9) Okada A, et al : Symptom Perception, Evaluation, Response to Symptom. and Delayed Care Seeking in Patients With Acute Heart Failure : An Observational Study. J Cardiovasc Nurs 34 : 36-43, 2019.
PubMed
10) Riegel B, et al : A mixed methods study of symptom perception in patients with chronic heart failure. Heart Lung 47 : 107-114, 2018.
PubMed
11) 中根英策, ほか : 高齢心不全患者に対する再入院防止の試み-体重と症状の点数化と地域連携で再入院を防ぐ-. 心臓リハビリテーション 23 : 128-131, 2017.
Medical*Online
12) Riegel B, et al : Symptom recognition in elders with heart failure. J Nurs Scholarsh 42 : 92-100, 2010.
PubMed
13) Jurgens CY, et al : Why do elders delay responding to heart failure symptoms? Nurs Res 58 : 274-282, 2009.
PubMed
14) Bekelman DB, et al : Primary Results of the Patient-Centered Disease Management (PCDM) for Heart Failure Study : A Randomized Clinical Trial. JAMA Intern Med 175 : 725-732, 2015.
PubMed
15) Evangelista LS, et al : Examining the effects of an outpatient palliative care consultation on symptom burden, depression, and quality of life in patients with symptomatic heart failure. J Card Fail 18 : 894-899, 2012.
PubMed
P.21 掲載の参考文献
1) Goodlin SJ : Palliative care in congestive heart failure. J Am Coll Cardiol 54 : 386-396, 2009.
PubMed
2) Tsuchihashi M, et al : Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. Am Heart J 142 : E7, 2001.
PubMed
3) van der Wal MH, et al : Compliance with non-pharmacological recommendations and outcome in heart failure patients. Eur Heart J 31 : 1486-1493, 2010.
PubMed
4) 筒井裕之, ほか : 急性・慢性心不全治療ガイドライン (2017年改訂版). 日本循環器学会/日本心不全学会合同ガイドライン. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年2月閲覧)
 
5) Riegel B, et al : State of the science : promoting self-care in persons with heart failure : a scientific statement from the American Heart Association. Circulation 120 : 1141-1163, 2009.
PubMed
6) Riegel B, et al : The Situation-Specific Theory of Heart Failure Self-Care : Revised and Updated. J Cardiovasc Nurs 31 : 226-235, 2016.
PubMed
7) 林亜希子, ほか : 心不全患者の服薬行動に関する研究の動向と課題 : Systematic Reviewからの考察. 心臓 50 : 152-163, 2018.
Medical*Online
8) Basuray A, et al : Dietary sodium adherence is poor in chronic heart failure patients. J Card Fail 21 : 323-329, 2015.
PubMed
9) Lee S, Riegel B : State of the Science in Heart Failure Symptom Perception Research : An Integrative Review. J Cardiovasc Nurs 33 : 204-210, 2018.
PubMed
10) 岡田明子, 眞茅みゆき : 心不全患者の受診行動に関する「症状の自覚」, 「症状の評価」, 「症状への対処行動」に関する研究の現状と課題. 日本循環器看護学会誌 11 : 30-38, 2016.
 
11) Matsuoka S, et al : Development and Validation of a Heart Failure-Specific Health Literacy Scale. J Cardiovasc Nurs 31 : 131-139, 2016.
PubMed
12) Moser DK, et al : Vulnerabilities of patients recovering from an exacerbation of chronic heart failure. Am Heart J 150 : 984, 2005.
PubMed
13) Basuray A, et al : Dietary sodium adherence is poor in chronic heart failure patients. J Card Fail 21 : 323-329, 2015.
PubMed
14) Xu J, et al : Heart Failure Rehospitalization and Delayed Decision Making : The Impact of Self-care and Depression. J Cardiovasc Nurs 33 : 30-39, 2018.
PubMed
P.27 掲載の参考文献
1) Molloy GJ, et al : Effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress. Eur J Cardiovasc Prev Rehabil 13 : 381-387, 2006.
PubMed
2) Herridge ML, Linton JC : Psychosocial Issues and Strategies. In : AACVPR Cardiac Rehabilitation Resource Manual : Promoting Health and Preventing Disease (ed by American Association of Cardiovascular & Pulmonary Rehabilitation), p43-50, Human Kinetics, Champaign, 2005.
 
3) Yohannes AM, et al : Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease : prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 25 : 1209-1221, 2010.
PubMed
4) Rutledge T, et al : Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48 : 1527-1537, 2006.
PubMed
5) American Heart Association : 1998 Heart and Stroke Statistical Update. American Heart Association, Dallas, Texas, 1998.
 
6) Hawthorne MH, Hixon ME : Functional status, mood disturbance and quality of life in patients with heart failure. Prog Cardiovasc Nurs 9 : 22-32, 1994.
PubMed
7) Vavouranakis I, et al : Effect of home-based intervention on hospital readmission and quality of life in middle-aged patients with severe congestive heart failure : a 12-month follow up study. Eur J Cardiovasc Nurs 2 : 105-111, 2003.
PubMed
8) Gathright EC, et al : Depression increases the risk of mortality in patients with heart failure : A meta-analysis. J Psychosom Res 94 : 82-89, 2017.
PubMed
9) Rose C, et al : The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD) : a systematic review. Patient Educ Couns 47 : 311-318, 2002.
PubMed
10) Jeyanantham K, et al : Effects of cognitive behavioural therapy for depression in heart failure patients : a systematic review and meta-analysis. Heart Fail Rev 22 : 731-741, 2017.
PubMed
11) Ghasemi E, et al : Mental health in family caregivers of patients with heart failure. Nurs Pract Today 1 : 63-70, 2014.
 
12) Gure TR, et al : Degree of disability and patterns of caregiving among older Americans with congestive heart failure. J Gen Intern Med 23 : 70-76, 2008.
PubMed
13) Chung ML, et al : Depressive symptoms in patients with heart failure negatively affect family caregiver outcomes and quality of life. Eur J Cardiovasc Nurs 15 : 30-38, 2016.
PubMed
14) Saunders MM : Indicators of health-related quality of life in heart failure family caregivers. J Community Health Nurs 26 : 173-182, 2009,
PubMed
15) Evangelista LS, et al : An integrated review of interventions to improve psychological outcomes in caregivers of patients with heart failure. Curr Opin Support Palliat Care 10 : 24-31, 2016.
PubMed
P.32 掲載の参考文献
1) 日本臓器移植ネットワーク : 移植に関するデータ [http://www.jotnw.or.jp/datafile/] (2019年2月閲覧)
 
2) Nakatani T, et al : Japanese registry for Mechanically Assisted Circulatory Support : First report. J Heart Lung Transplant 36 : 1087-1096, 2017.
PubMed
3) 医薬品医療機器総合機構医療情報活用推進室 : 日本における補助人工心臓に関連した市販後のデータ収集. J-MACS Statistical Report, 2017. [https://www.pmda.go.jp/files/000218006.pdf] (2019年2月閲覧)
 
4) Kato N, et al : Learning self-care after left ventricular assist device implantation. Curr Heart Fail Rep 11 : 290-298, 2014.
PubMed
P.37 掲載の参考文献
1) 厚生労働省 人生の最終段階における医療の普及・啓発の在り方に関する検討会 : 平成29年度人生の最終段階における医療に関する意識調査報告書. [https://www.mhlw.go.jp/toukei/list/dl/saisyuiryo_a_h29.pdf] 厚生労働省 (2019年2月閲覧)
 
2) Desai AS, et al : Rehospitalization for heart failure : predict or prevent? Circulation 126 : 501-506, 2012.
 
3) Tsutsui H, et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006.
PubMed
4) 日本循環器学会, 日本心不全学会 : 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版), p104-105, 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2018年12月閲覧)
 
5) Kelley AS, Morrison RS : Palliative Care for the Seriously Ill. N Engl J Med 373 : 747-755, 2015.
PubMed
6) 日本心不全学会ガイドライン委員会 (編) : 高齢心不全患者の治療に関するステートメント, p51, 2016. [http://www.asas.or.jp/jhfs/pdf/Statement_HeartFailurel.pdf] (2018年12月閲覧)
 
P.44 掲載の参考文献
1) 日本心不全学会 : 高齢心不全患者の治療に関するステートメント (日本心不全学会ガイドライン委員会編), p10, ライフサイエンス出版, 2016.
 
2) 眞茅みゆき, 筒井裕之 : 日本および海外における心不全の現状. 心不全ケア教本 (眞茅みゆき, ほか編), p15, メディカル・サイエンス・インターナショナル, 2012.
 
3) 日本循環器学会/日本心不全学会合同ガイドライン合同研究班 (班長筒井裕之) : 急性・慢性心不全診療ガイドライン (2017年改訂版), p104, 2018.
 
4) Fergenbaum J, et al : Care in the Home for the Management of Chronic Heart Failure : Systematic Review and Cost-Effectiveness Analysis. J Cardiovasc Nurs 30 : S44-51, 2015.
PubMed
5) Tsuchihashi-Makaya M, et al : Home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J 77 : 926-933, 2013.
PubMed
6) 齊藤訓子 : 訪問看護の新たな展開-「生活を支える看護」の最前線としての役割. 平成29年版看護白書 (日本看護協会編), p6, 日本看護協会出版会, 2017.
 
7) 山田雅子 : 訪問看護の役割・機能・特性. 訪問看護基本テキスト総論編 (日本訪問看護財団監修), p11-22, 日本看護協会出版会, 2018.
 
8) 全国訪問看護事業協会 : 平成30年度訪問看護ステーション数調査結果 (訪問看護ステーション), 2018. [https://www.zenhokan.or.jp/wp-content/uploads/h30-research.pdf] (2019年1月閲覧)
 
9) 厚生労働省 : 3. 訪問看護ステーション利用者の状況. 平成28年介護サービス施設・事業所調査の概況, 2017. [https://www.mhlw.go.jp/toukei/saikin/hw/kaigo/service16/dl/kekka-gaiyou_03.pdf] (2019年1月閲覧)
 
10) e-Stat : 訪問看護ステーションの利用者数, 傷病分類, 要介護 (支援) 度-適用法別. 平成28年介護サービス施設・事業所調査 (厚生労働省), 2017. [https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450042&tstat=000001029805&cycle=7&tclass1=000001106635&tclass2=000001106640&tclass3=000001106644&tclass4=000001106675&second2=1] (2019年1月閲覧)
 
11) 菱田一恵 : 在宅療養者の特性. 訪問看護基本テキスト総論編 (日本訪問看護財団監修), p180-181, 日本看護協会出版会, 2018.
 
P.51 掲載の参考文献
1) Horwitz LI, et al : Quality of discharge practices and patient understanding at an academic medical center. JAMA Intern Med 173 : 1715-1722, 2013.
PubMed
2) 日本看護協会 : 平成22年度業務委員会「外来における看護の専門性の発揮に向けた課題」. [https://www.nurse.or.jp/home/publication/pdf/fukyukeihatsu/gairaikango0731.pdf]
 
3) Tsuchihashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure : A study in Fukuoka, Japan. Jpn Circ J 64 : 953-959, 2000.
PubMed
4) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf]
 
5) 日本循環器学会 : 『心不全の定義」について (2017年10月31日発表). [http://www.j-circ.or.jp/five_year/teigi_qa.pdf] (2019年2月閲覧)
 
6) 中野直美 : 退院後, どのように患者さんにかかわるべきか? ナースがわかる&はなせる心不全まるわかりBOOK (佐藤直樹監修), HEART nursing 2016年春季増刊, 通巻388号, p153-159, メディカ出版, 2016.
 
7) Kato N, et al : Validity and reliability of the Japanese version of the European Heart Failure Self-Care Behavior Scale. Eur J Cardiovasc Nurs 7 : 284-289, 2008.
PubMed
8) 日本心不全学会ガイドライン委員会 (編) : 心不全患者における栄養評価・管理に関するステートメント, 2018.
 
9) Sasayama S, et al : New Aspects in the Treatment of Failing Heart (ed by Yasuda H, Kawaguchi H), p113-117, Springer-Verlag, 1992.
 
10) Snaith RP : The Hospital Anxiety And Depression Scale, Health Qual Life Outcomes 1 : 29, 2003.
PubMed
11) Kitakata H, et al : Patient confidence regarding secondary lifestyle modification and knowledge of 'heart attack' symptoms following percutaneous revascularisation in Japan : a cross-sectional study. BMJ Open 8 : e019119, 2018.
PubMed
12) Allen LA, et al : Decision making in advanced heart failure : a scientific statement from the American Heart Association. Circulation 125 : 1928-1952, 2012.
PubMed
13) 和泉徹ほか (監) : 心不全を予防する-発症させない再発させないための診療ストラテジ-, 中山書店, 2006.
 
14) 眞茅みゆき, ほか (編) : 心不全ケア教本, p281, メディカル・サイエンス・インターナショナル, 2012.
 
P.57 掲載の参考文献
1) WRITING COMMITTEE MEMBERS ; Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
 
2) Okura Y, et al : Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J 72 : 489-491, 2008.
 
3) Stromberg A, et al : Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure : results from a prospective, randomised trial. Eur Heart J 24 : 1014-1023, 2003.
PubMed
4) McAlister FA, et al : Multidisciplinary strategies for the management of heart failure patients at high risk for admission : a systematic review of randomized trials. J Am Coll Cardiol 44 : 810-819, 2004.
PubMed
5) Kitagawa T, et al : Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels. PLoS ONE 13 : e0190979, 2018.
PubMed
6) Tsuchihashi-Makaya M, et al : Home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J 77 : 926-933, 2013.
PubMed
7) Kotooka N, et al : Home telemonitoring study for Japanese patients with heart failure (HOMES-HF) : protocol for a multicentre randomised controlled trial. BMJ Open 3 : e002972, 2013. (doi : 10.1136/bmjopen-2013-002972)
 
P.64 掲載の参考文献
1) Festa JR, et al : Association of low ejection fraction with impaired verbal memory in older patients with heart failure. Arch Neurol 68 : 1021-1026, 2011.
PubMed
2) Zuccala G, et al : Correlates of cognitive impairment among patients with heart failure : results of a multicenter survey. Am J Med 118 : 496-502, 2005.
PubMed
3) Almeida OP, Tamai S : Congestive heart failure and cognitive functioning amongst older adults. Arq Neuropsiquiatr 59 : 324-329, 2001.
PubMed
4) Acanfora D, et al : The brain in congestive heart failure. Arch Gerontol Geriatr 23 : 247-256, 1996.
PubMed
5) Cacciatore F, et al : Congestive heart failure and cognitive impairment in an older population. Osservatorio Geriatrico Campano Study Group. J Am Geriatr Soc 46 : 1343-1348, 1998.
 
6) Sauve MJ, et al : Cognitive impairments in chronic heart failure : a case controlled study. J Card Fail 15 : 1-10, 2009.
PubMed
7) Trojano L, et al : Cognitive impairment : akey feature of congestive heart failure in the elderly. J Neurol 250 : 1456-1463, 2003.
 
8) Almeida OP, et al : Two-year course of cognitive function and mood in adults with congestive heart failure and coronary artery disease : the Heart-Mind Study. Int Psychogeriatr 24 : 38-47, 2012.
PubMed
9) Jefferson AL, et al : Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am J Cardiol 108 : 1346-1351, 2011.
PubMed
10) Qiu C, et al : Heart failure and risk of dementia and Alzheimer disease : a population-based cohort study. Arch Intern Med 166 : 1003-1008, 2006.
PubMed
11) Putzke JD, et al : Neuropsychological functioning among heart transplant candidates : a case control study. J Clin Exp Neuropsychol 22 : 95-103, 2000.
PubMed
12) Ekman I, et al : The clinical implications of cognitive impairment in elderly patients with chronic heart failure. J Cardiovasc Nurs 16 : 47-55, 2001.
PubMed
13) Cermakova P, et al : Heart failure and dementia : survival in relation to types of heart failure and different dementia disorders. Eur J Heart Fail 17 : 612-619, 2015.
PubMed
14) Vogels RL, et al : Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 9 : 1003-1009, 2007.
PubMed
15) van Beek AH, et al : Cerebral autoregulation : an overview of current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab 28 : 1071-1085, 2008.
PubMed
16) Pantoni L : Cerebral small vessel disease : from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9 : 689-701, 2010.
PubMed
17) Chen J, et al : Diabetic cardiomyopathy and its prevention by nrf2 : current status. Diabetes Metab J 38 : 337-345, 2014.
PubMed
18) Gupta A, Iadecola C : Impaired Aβ clearance : a potential link between atherosclerosis and Alzheimer's disease. Front Aging Neurosci 7 : 115, 2015.
 
19) Lassen NA : Cerebral blood flow and oxygen consumption in man. Physiol Rev 39 : 183-238, 1959.
PubMed
20) Massaro AR, et al : Transcranial Doppler assessment of cerebral blood flow : effect of cardiac transplantation. Neurology 66 : 124-126, 2006.
PubMed
21) Gruhn N, et al : Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 32 : 2530-2533, 2001.
PubMed
22) Pluta R : The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemiareperfusion brain injury. A model of early Alzheimer's disease. Ann N Y Acad Sci 903 : 324-334, 2000.
 
23) Aliev G, et al : Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4 : 649-663, 2004.
PubMed
24) Jefferson AL : Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis 20 : 813-821, 2010.
PubMed
25) Kalantarian S, et al : Cognitive impairment associated with atrial fibrillation : a meta-analysis. Ann Intern Med 158 : 338-346, 2013.
PubMed
26) 平成23～24年度 厚生労働科学研究費補助金 認知症対策総合研究事業「都市部における認知症有病率と認知症の生活機能障害への対応」 (代表研究者 : 朝田隆), 2013.
 
27) 日本老年医学会 (編) : 高齢者の服薬管理. 健康長寿診療ハンドブック, p109, メジカルビュー, 2011.
 
28) 日本老年医学会 (編) : 高齢者の安全な薬物療法ガイドライン 2015, メジカルビュー, 2015.
 
29) Intzandt B, et al : Is Cardiac Rehabilitation Exercise Feasible for People with Mild Cognitive Impairment? Can Geriatr J 18 : 65-72, 2015.
PubMed
P.70 掲載の参考文献
1) 山田豊子 : 日本手術室看護の歴史から観た専門性の課題. 京都市立看護短期大学紀要 33 : 29-37, 2008.
 
2) 土藏愛子 : 手術看護に見る匠の技, 東京医学社, 2012.
 
3) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版), p105-111, 2018.
 
4) 日本循環器学会 : 循環器疾患診療実態調査報告書 (2017年度実施・公表), p14, 2017.
 
5) 日本心臓リハビリテーション学会 : 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版), p42-51, 2013.
 
6) 西村真人, ほか : 術前低移動能力は, 冠動脈バイパス術後の歩行回復に影響する. 心臓リハビリテーション (JJCR) 20 : 179-184, 2015.
 
7) Kobayashi A, et al : Structure of the Will of Recovery in the Patients Who Underwent Heart Surgery. Journal of Japan Academy of Critical Care Nursing 10 : 41-50, 2014.
 
8) Shiraishi Y, et al : 9-Year Trend in the Management of Acute Heart Failure in Japan : A Report From the National Consortium of Acute Heart Failure Registries. J Am Heart Assoc 7 : e008687, 2018. (doi : 10.1161/JAHA.118.008687)
 
9) https://kotobank.jp/word/レディネス-151776
 
10) 日本麻酔科学会・周術期管理チーム委員会 (編) : 周術期管理チームテキスト, 第3版, 公益社団法人日本麻酔科学会, 2016.
 
11) 鈴木陽子, ほか : アセスメントポイントがひとめでわかる ICUナースのための循環&呼吸管理と術前・術後ケア (小谷透監修), メディカ出版, 2012.
 
P.76 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版), p1-143, ライフサイエンス出版, 2018.
 
2) 日本呼吸器学会NPPVガイドライン作成委員会 (編) : NPPV (非侵襲的陽圧換気療法) ガイドライン (改訂第2版), p77-85, p124-131, 南江堂, 2015.
 
3) 循環器病の診断と治療に関するガイドライン 2008-2009年度合同研究班 : 循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン. Circ J 74 (Suppl II) : 963-1052, 2010.
 
4) 加藤隆生, 葛西隆敏 : 心不全のCPAP治療. MB ENTONI 191 : 71-79, 2016.
Medical*Online
5) Kasai T, et al : Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest 133 : 690-696, 2008.
PubMed
6) Arzt M, et al : Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure : a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 115 : 3173-3180, 2007.
PubMed
7) 葛西隆敏 : 睡眠呼吸障害に対するCPAPおよびASV療法. 日本呼吸ケア・リハビリテーション学会誌 26 : 16-20, 2016.
 
8) Cowie MR, et al : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 373 : 1095-1105, 2015.
PubMed
9) 川上重彦 : ベストプラクティス医療関連機器圧迫創傷の予防と管理 (一般社団法人日本褥瘡学会編), 2016.
 
10) Yamaguchi T, et al : Outcomes after delirium in a Japanese intensive care unit. Gen Hosp Psychiatry 36 : 634-636, 2014.
 
11) 日本集中治療医学会J-PADガイドライン作成委員会 : 日本版・集中治療室における成人重症患者に対する痛み・不穏・せん妄管理のための臨床ガイドライン. 日集中医誌 21 : 539-579, 2014.
 
12) Huang Z, et al : Dexmedetomidine versus midazolam for the sedation of patients with non-invasive ventilation failure. Intern Med 51 : 2299-2305, 2012.
PubMed
P.83 掲載の参考文献
1) Isogai T, et al : Clinical features and peripartum outcomes in pregnant women with cardiac disease : a nationwide retrospective cohort study in Japan. Heart Vessels 33 : 918-930, 2018.
PubMed
2) Drenthen W, et al : Outcome of pregnancy in women with congenital heart disease : a literature review. J Am Coll Cardiol 49 : 2303-2311, 2007.
PubMed
2) 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告) 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2010年改訂版), 2011. [http://www.j-circ.or.jp/guideline/pdf/JCS2010niwa.h.pdf]
 
4) Steer PJ, Gatzoulis MA (ed) : Heart Disease and Pregnancy, second edition, p19-26, Cambridge University Press, Cambridge, 2016.
 
5) Peck TM, Arias F : Hematologic changes associated with pregnancy. Clin Obstet Gynecol 22 : 785-798, 1979.
PubMed
6) Ruys TP, et al : Heart failure in pregnant wornen with cardiac disease : data from the ROPAC. Heart 100 : 231-238, 2014.
 
7) Silversides CK, et al : Pregnancy Outcomes in Women With Heart Disease : The CARPREG II Study. J Am Coll Cardiol 71 : 2419-2430, 2018.
PubMed
8) Regitz-Zagrosek V, et al : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 39 : 3165-3241, 2018.
 
9) Drenthen W, et al : Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 31 : 2124-2132, 2010.
PubMed
10) Ohuchi H, et al : Cardiopulmonary variables during exercise predict pregnancy outcome in women with congenital heart disease. Circ J 77 : 470-476, 2013.
PubMed
P.88 掲載の参考文献
1) Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
 
2) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 : 891-975, 2016.
 
3) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf]
 
4) Tsutsui H, et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006.
PubMed
5) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
6) Takano H, et al : Effects of pitavastatin in Japanese patients with chronic heart failure : the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77 : 917-925, 2013.
PubMed
7) Cheng JW : Current perspectives on the role of the pharmacist in heart failure management. Integr Pharm Res Pract 7 : 1-11, 2017.
PubMed
8) Di Palo KE, et al : Improving Provider Adherence to Guideline Recommendations in Heart Failure. Curr Heart Fail Rep 15 : 350-356, 2018.
PubMed
9) Murray MD, et al : Factors associated with exacerbation of heart failure include treatment adherence and health literacy skills. Clin Pharmacol Ther 85 : 651-658, 2009.
PubMed
10) Davis EM, et al : The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm 20 : 741-755, 2014.
PubMed
11) Riles EM, et al : Medication adherence and heart failure. Curr Cardiol Rep 16 : 458, 2014.
PubMed
12) Ruppar TM, et al : Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates : Systematic Review and Meta-Analysis of Controlled Trials. J Am Heart Assoc 5 : 2016.
PubMed
13) Murray MD, et al : Pharmacist intervention to improve medication adherence in heart failure : a randomized trial. Ann Intern Med 146 : 714-725, 2007.
PubMed
14) Suzuki M, et al : Pharmacist-led intervention in the multidisciplinary team approach optimizes heart failure medication. Heart Vessels 33 : 615-622, 2018.
PubMed
15) Takano H : Home Medical Care for Heart Failure Patients : Pharmaceutical Education Program of Chiba University. Yakugaku Zasshi 138 : 783-785, 2018.
PubMed

XX 心不全の併存症 - 病態・治療 -

P.96 掲載の参考文献
1) 井上博, ほか : 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告) 心房細動治療 (薬物) ガイドライン (2013年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf]
 
2) Rawles JM : What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 63 : 157-161, 1990.
PubMed
3) Nagai R, et al : Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J 77 : 908-916, 2013.
 
4) Kirchhof P, et al : 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 : 2893-2962, 2016. (doi : 10.1093/eurheartj/ehw210)
 
5) Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 18 : 649-654, 1997.
 
6) Van Gelder IC, et al : Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362 : 1363-1373, 2010.
PubMed
7) Whitbeck MG, et al : Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 34 : 1481-1488, 2013.
PubMed
8) van Veldhuisen DJ, et al : Digoxin for patients with atrial fibrillation and heart failure : paradise lost or not? Eur Heart J 34 : 1468-1470, 2013.
PubMed
9) Yamashita T, Inoue H : Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation : results of the MAIN-AF study. J Cardiol 62 : 50-57, 2013.
PubMed
10) Lundstrom T, Ryden L : Ventricular rate control and exercise performance in chronic atrial fibrillation : effects of diltiazem and verapamil. J Am Coll Cardiol 16 : 86-90, 1990.
PubMed
P.102 掲載の参考文献
1) Iwasaki YK, et al : Atrial fibrillation pathophysiology : implications for management. Circulation 124 : 2264-2274, 2011.
PubMed
2) Mamas MA, et al : A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11 : 676-683, 2009.
PubMed
3) Gopinathannair R, et al : Arrhythmia-Induced Cardiomyopathies : Mechanisms, Recognition, and Management. J Am Coll Cardiol 66 : 1714-1728, 2015.
PubMed
4) Roy D, et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 : 2667-2677, 2008.
PubMed
5) Haissaguerre M, et al : Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 : 659-666, 1998.
PubMed
6) Di Biase L, et al : Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device : Results From the AATAC Multicenter Randomized Trial. Circulation 133 : 1637-1644, 2016.
 
7) Marrouche NF, et al : Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 378 : 417-427, 2018.
PubMed
8) Calkins H, et al : 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 14 : e275-e444, 2017. (doi : 10.1016/j.hrthm2017.05.012)
 
9) Friberg L, et al : Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death : data from Swedish health registries. Eur Heart J 37 : 2478-2487, 2016.
PubMed
P.109 掲載の参考文献
1) Connolly SJ, et al : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 : 1139-1151, 2009.
PubMed
2) Patel MR, et al : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 : 883-891, 2011.
PubMed
3) Granger CB, et al : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 : 981-992, 2011.
PubMed
4) Giugliano RP, et al : Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 : 2093-2104, 2013.
PubMed
5) Larsen TB, et al : Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation : propensity weighted nationwide cohort study. BMJ 353 : i3189, 2016.
PubMed
6) Chan YH, et al : Thromboembolic, Bleeding. and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. J Am Coll Cardiol 68 : 1389-1401, 2016.
PubMed
7) Kodani E, et al : Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation-Results of the J-RHYTHM Registry 2. Circ J 80 : 843-851, 2016.
 
8) Yamashita Y, et al : Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients-Fushimi AF Registry. Circ J 81 : 1278-1285, 2017.
PubMed
9) Steinberg BA, et al : Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants : Results From ORBIT-AFII (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 7 : e007633, 2018. (doi : 10.1161/JAHA.117.007633)
 
10) Dewilde WJ, et al : Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial. Lancet 381 : 1107-1115, 2013.
 
11) Gibson CM, et al : Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 375 : 2423-2434, 2016.
PubMed
12) Cannon CP, et al : Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 377 : 1513-1524, 2017.
PubMed
13) Lopes RD, et al : An open-Label, 2×2factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention : Rationale and design of the AUGUSTUS trial, Am Heart J 200 : 17-23, 2018.
 
14) Vranckx P, et al : Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement : Rationale and design of the ENTRUST-AF PCI trial. Am Heart J 196 : 105-112, 2018.
PubMed
15) Koretsune Y, et al : Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J 79 : 1486-1495, 2015.
PubMed
16) Shah M, et al : Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129 : 1196-1203, 2014.
PubMed
17) Sharma M, et al : Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism : Systematic Review and Meta-Analysis. Circulation 132 : 194-204, 2015.
PubMed
18) Chao TF, et al : Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation : A Nationwide Cohort Study. Circulation 138 : 37-47, 2018.
PubMed
19) Pollack CV, et al : Idarucizumab for Dabigatran Reversal. N Engl J Med 373 : 511-520, 2015.
PubMed
20) Connolly SJ, et al : Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 375 : 1131-1141, 2016.
PubMed
P.115 掲載の参考文献
1) Hara H, et al : The left atrial appendage. Anatomy, physiology, and therapeutic percutaneous closure. In : Textbook of Interventional Cardiology (ed by Topol EJ, Teirstein PS), 5th ed, p863-877, Saunders, Philadelphia, 2007.
 
2) Reddy VY, et al : Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation : a randomized clinical trial. JAMA 312 : 1988-1998, 2014.
PubMed
3) Hara H, et al : Percutaneous left atrial appendage obliteration. JACC Cardiovasc Imaging 1 : 92-93, 2008.
PubMed
4) Landmesser U, et al : Left atrial appendage occlusion with the AMPLATZER Amulet device : periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention 13 : 867-876, 2017.
PubMed
P.121 掲載の参考文献
1) Santangeli P, et al : Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure. J Am Coll Cardiol 69 : 1842-1860, 2017.
PubMed
2) Cardiac Arrhythmia Suppression Trial (CAST) Investigators : Preliminary report : effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 : 406-412, 1989.
 
3) 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2018年12月24日閲覧)
 
4) 心筋梗塞二次予防に関するガイドライン (2011年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf] (2018年12月24日閲覧)
 
5) Chadda K, et al : Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73 : 503-510, 1986.
PubMed
6) McMurray J, et al : Antiarrhythmic effect of carvedilol after acute myocardial infarction : results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 : 525-530, 2005.
 
7) Al-Khatib SM, et al : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation 138 : e272-e391, 2018.
PubMed
8) Connolly SJ, et al : Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators : the OPTIC Study : a randomized trial. JAMA 295 : 165-171, 2006,
PubMed
9) Sorajja D, et al : Optimal antiarrhythmic drug therapy for electrical storm. J Biomed Res 29 : 20-34, 2015.
 
10) Chatzidou S, et al : Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. J Am Coll Cardiol 71 : 1897-1906, 2018.
PubMed
11) Chakir K, et al : Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation 119 : 1231-1240, 2009.
PubMed
12) Santangeli P, et al : Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators : A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm 13 : 1552-1559, 2016.
PubMed
13) Sapp JL, et al : Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med 375 : 111-121, 2016.
PubMed
14) Gao D, et al : Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J Cardiovasc Pharmacol 62 : 199-204, 2013.
PubMed
15) Otuki S, et al : The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias. J Electrocardiol 50 : 277-281, 2017.
PubMed
16) Deyell MW, et al : Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol 29 : 603-608, 2018.
PubMed
17) Aiba T, et al : Cardiac resynchronization therapy improves altered Na channel gating in canine model of dyssynchronous heart failure. Circ Arrhythm Electrophysiol 6 : 546-554, 2013.
PubMed
P.129 掲載の参考文献
1) Niwano S, et al : Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 95 : 1230-1237, 2009.
PubMed
2) Takernoto M, et al : Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 45 : 1259-1265, 2005.
 
3) Wang Y, et al : Cellular mechanism of premature ventricular contraction-induced cardiomyopathy. Heart Rhythm 11 : 2064-2072, 2014.
PubMed
4) 夛田浩 : 12 誘導心電図波形を用いた特発性心室不整脈起源の診断. 心電図 30 : 453-465, 2010.
 
5) Sapp JL, et al : Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med 375 : 111-121, 2016.
PubMed
6) Stevenson WG, et al : Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction : the multicenter thermocool ventricular tachycardia ablation trial. Circulation 118 : 2773-2782, 2008.
PubMed
7) Tung R, et al : Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease : An International VT Ablation Center Collaborative Group study. Heart Rhythm 12 : 1997-2007, 2015.
 
8) Valles E, et al : ECG criteria to identify epicardial ventricular tachycardia in nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol 3 : 63-71, 2010.
PubMed
9) Sacher F, et al : Substrate mapping and ablation for ventricular tachycardia : the LAVA approach. J Cardiovasc Electrophysiol 26 : 464-471, 2015.
PubMed
10) Bansch D, et al : Successful catheter ablation of electrical storm after myocardial infarction. Circulation 108 : 3011-3016, 2003.
PubMed
11) Nogami A : Trigger elimination of polymorphic ventricular tachycardia and ventricular fibrillation by catheter ablation : trigger and substrate modification. J Biomed Res 29 : 44-51, 2015.
PubMed
P.136 掲載の参考文献
1) Kusumoto FM, et al : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 2018. (doi : 10.1016/j.jacc.2018.10.044)
 
2) 不整脈の非薬物治療ガイドライン (2011年改訂版). 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告), 2012.
 
3) Sweeney MO, et al : Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107 : 2932-2937, 2003.
 
4) Leclercq C, et al : Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure : The RD-CHF Study. Pacing Clin Electrophysiol 30 (Suppl 1) : S23-30, 2007.
 
5) Hussain MA, et al : The Effect of Right Ventricular Apical and Nonapical Pacing on the Short- and Long-Term Changes in Left Ventricular Ejection Fraction : A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Pacing Clin Electrophysiol 38 : 1121-1136, 2015.
 
6) Jones S, et al : Applicability of the iterative technique for cardiac resynchronization therapy optimization : full-disclosure, 50-sequential-patient dataset of transmitral Doppler traces. with implications for future research design and guidelines. Europace 16 : 541-550, 2014.
PubMed
P.143 掲載の参考文献
1) Piccini JP, et al : Amiodarone for the prevention of sudden cardiac death : a meta-analysis of randomized controlled trials. Eur Heart J 30 : 1245-1253, 2009.
PubMed
2) Connolly SJ, et al : Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators : the OPTIC Study : a randomized trial. JAMA 295 : 165-171, 2006.
PubMed
3) Nagai R, et al : Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J 77 : 908-916, 2013.
 
4) Kotecha D, et al : Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 384 : 2235-2243, 2014.
 
5) Li SJ, et al : Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction : Findings From the Swedish Heart Failure Registry. Circ Heart Fail 8 : 871-879, 2015.
 
6) Kirchhof P, et al : 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 : 2893-2962, 2016.
PubMed
7) 児玉逸雄 : アミオダロンの薬理作用. 循環器薬物治療実践シリーズ I 不整脈にアミオダロンをどう使うか-新たなエビデンスを加えて- (新版) (日本心電学会学術諮問. 委員会編), p9-25, ライフメディコム, 2010.
 
8) Shiga T, et al : Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 66 : 600-604, 2002.
 
9) Komatsu T, et al : Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 71 : 46-51, 2007.
PubMed
10) Yamada Y, et al : Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 71 : 1610-1616, 2007.
PubMed
11) 志賀剛 : アミオダロンの臨床使用と注意点. 循環器薬物治療実践シリーズ I 不整脈にアミオダロンをどう使うか-新たなエビデンスを加えて- (新版) (日本心電学会学術諮問委員会編), p27-48, ライフメディコム, 2010.
 
12) 加藤貴雄ほか : MS-551注射剤の第I相試験 (第1報) -単回投与試験-. 臨床医薬 13 : 1659-1674, 1997.
Medical*Online
13) Wang T, et al : Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 57 : 1160-1165, 1986,
PubMed
14) 日本循環器学会/日本TDM学会合同ガイドライン (2013～2014年度合同研究班報告) : 2015年版循環器薬の薬物血中濃度モニタリングに関するガイドライン, 2015. [http://plaza.umin.ac.jp/~jstdm/guidelines/JCS2015_Original.pdf] (2019年3月閲覧)
 
15) Rathore SS, et al : Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 : 871-878, 2003.
PubMed
P.156 掲載の参考文献
1) 井川修 : 臨床心臓構造学-不整脈診療に役立つ心臓解剖. 医学書院, 2011.
 
2) Igawa O, et al : Extension of the inferior vena cava into the posteroinferior right atrium. Heart Rhythm Dec 3 : 1481-1485, 2006.
PubMed
3) Van Praagh R, Corsini I : Cor tritriatum, pathologic anatomy and a consideration of morphogenesis based on 13 postmortem cases and a study of normal development of the pulmonary vein and atrial septum in 83 human embryos. Am Heart J 78 : 379-405, 1969.
 
4) Igawa O : Focus on the Atrial Structure-Useful Anatomical Information for Catheter Ablation-. J Arrhythmia 27 : 268-288, 2011.
 
5) 井川修, ほか : 左房前壁に潜在する特殊な解剖学的構造. 心電図 28 : 574-581, 2008.
Medical*Online
6) Igawa O, et al : Specific Myocardial Bundle of the Left Atrium, Right Lateral Ridge (E30-9). The 83th Annual Scientific Meeting of the Japanese Circulation Society. 3. 31. 2019.
 
7) Haissaguerre M, et al : Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. N Engl J Med 339 : 659-666, 1998.
PubMed
8) Chen SA, et al : Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins : electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 100 : 1879-1886, 1999.
PubMed
9) 井川修 : 基礎・心臓構造からみた心房細動. 不整脈 2017 (杉本恒明監修, 井上博編), メディカルレビュー社, p30-39, 2017.
 
P.161 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
2) American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
 
3) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
 
4) Tsutsui H, et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006.
PubMed
5) Kajimoto K et al : Etiology of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction. Am J Cardiol 118 : 1881-1887, 2016.
 
6) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
7) Shimokawa H, et al : Heart failure as a general pandemic in Asia. Eur J Heart Fail 17 : 884-892, 2015.
 
8) Ushigome R, et al : Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan-report from the CHART Studies. Circ J 79 : 2396-2407, 2015.
PubMed
9) Shiba N, et al : Analysis of chronic heart failure registry in the Tohoku district : third year follow-up. Circ J 68 : 427-434, 2004.
PubMed
10) Tsuji K, et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19 : 1258-1269, 2017.
 
11) JCS Joint Working Group : Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). Circ J 77 : 249-274, 2013.
 
12) Satake H, et al : Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure-a report from the CHART-2 Study. Circ J 79 : 381-390, 2015.
PubMed
13) Zinman B, et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015.
PubMed
14) CANVAS Program Collaborative Group ; Neal B, et al : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377 : 644-657, 2017.
 
15) Stone NJ, et al : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : S1-45, 2014.
 
16) Catapano AL, et al : 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 37 : 2999-3058, 2016.
PubMed
17) Oikawa T, et al : Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease : A Report From the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study. J Am Heart Assoc 7 : e007524, 2018. (doi : 10.1161/JAHA.117.007524)
 
18) Sabatine MS, et al : Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376 : 1713-1722, 2017.
PubMed
19) Schwartz GG, et al : Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 379 : 2097-2107, 2018.
PubMed
P.165 掲載の参考文献
1) 大北裕, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版).
 
2) 筒井裕之, ほか : 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017改訂版).
 
3) Koelling TM, et al : Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 144 : 524-529, 2002.
PubMed
4) Trichon BH, et al : Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 91 : 538-543, 2003.
PubMed
5) Nishimura RA. et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : 2438-2488, 2014.
 
6) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
 
7) Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), et al : Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33 : 2451-2496, 2012.
 
8) Obadia JF, et al : Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379 : 2297-2306, 2018.
 
9) Stone GW. et al : Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
10) Yamashita E, et al : Prognostic value of paradoxical low-gradient severe aortic stenosis in Japan : Japanese Multicenter Aortic Stenosis Study, Retrospective (JUST-R) Registry. J Cardiol 65 : 360-368, 2015.
 
11) 中西敏雄, ほか : 2012-2013年度合同研究班報告 : 先天性心疾患, 心臓大血管の構造的疾患 (structural heart disease) に対するカテーテル治療のガイドライン (2014年版).
 
12) Abe Y, et al : Prevalence and Prognostic Significance of Functional Mitral and Tricuspid Regurgitation Despite Preserved Left Ventricular Ejection Fraction in Atrial Fibrillation Patients. Circ J 82 : 1451-1458, 2018.
PubMed
P.170 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版), 2017. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年4月閲覧)
 
2) 甲斐久史 : 慢性心不全の病態生理. 日本内科学会雑誌 101 : 322-328, 2012.
 
3) Zakeri R, Cowie MR : Heart failure with preserved ejection fraction : controversies, challenges and future directions. Heart 104 : 377-384, 2018.
PubMed
4) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37 : 2129-2200, 2016.
PubMed
5) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation 136 : e137-e161, 2017.
PubMed
6) Haider AW, et al : Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138 : 10-16, 2003.
PubMed
7) Ettehad D, et al : Blood pressure lowering for prevention of cardiovascular disease and death : a systernatic review and meta-analysis. Lancet 387 : 957-967, 2016.
 
8) Bavishi C, et al : Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. J Am Coll Cardiol 69 : 486-493, 2017.
PubMed
9) Zanchetti A, et al : Randomized controlled trials of blood pressure lowering in hypertension : a critical reappraisal. Circ Res 116 : 1058-1073, 2015.
PubMed
10) Davis BR. et al : Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 118 : 2259-2267, 2008.
PubMed
11) Sciarretta S, et al : Antihypertensive treatment and development of heart failure in hypertension : a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 171 : 384-394, 2011.
PubMed
12) Thomopoulos C, et al : Effects of blood pressure lowering on outcome incidence in hypertension : 4. Effects of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens 33 : 195-211, 2015.
PubMed
13) 高血圧治療ガイドライン 2019 (日本高血圧学会高血圧治療ガイドライン作成委員会編), ライフサイエンス出版, 2019.
 
14) Kawano H, et al : Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction : a systematic review and meta-analysis. Hypertens Res, ePub on April 25, 2019.
 
P.177 掲載の参考文献
1) Iribarren C, et al : Glycemic control and heart failure among adult patients with diabetes. Circulation 103 : 2668-2673, 2001.
PubMed
2) Udell JA, et al : Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes : a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 : 356-366, 2015.
 
3) Bugger H, Abel ED : Molecular mechanisms of diabetic cardiornyopathy. Diabetologia 57 : 660-671, 2014.
PubMed
4) MacDonald MR, et al : Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure : an analysis of the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 : 1377-1385, 2008.
PubMed
5) Paulus WJ. et al : A novel paradigm for heart failure with preserved ejection fraction : comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 : 263-271, 2013.
PubMed
6) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年3月閲覧)
 
7) Fitchett DH, et al : Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19 : 43-53, 2017.
 
8) Fitchett D, et al : Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk : results of the EMPA-REG OUTCOME trial. Eur Heart J 37 : 1526-1534, 2016.
PubMed
9) Fitchett D, et al : Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J 39 : 363-370, 2018.
PubMed
10) Mahaffey KW, et al : Canagliflozin for Primary and Secondary Prevention of Cardiovag. cular Events : Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 : 323-334, 2018.
 
11) Wiviott SD, et al : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380 : 347-357, 2019. [doi : 10.1056/NEJMoa1812389]
 
12) Heerspink HJ, et al : Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus : Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 134 : 752-772, 2016.
PubMed
13) Lahnwong S, et al : Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17 : 101, 2018.
PubMed
14) Farkouh ME, Verma S : Prevention of Heart Failure With SGLT-2 Inhibition : Insights From CVDREAL. J Am Coll Cardiol 71 : 2507-2510, 2018.
PubMed
15) Butler J, et al : The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. Eur J Heart Fail 19 : 1390-1400, 2017.
 
P.185 掲載の参考文献
1) Laufs U, et al : Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 : 1129-1135, 1998.
PubMed
2) Thavendiranathan P, et al : Primary prevention of cardiovascular diseases with statin therapy : a meta-analysis of randomized controlled trials. Arch Intern Med 166 : 2307-2313, 2006.
PubMed
3) Nakamura H, et al : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006.
PubMed
4) Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 : 1349-1357, 1998.
 
5) Taguchi I, et al : High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) : A Randomized Superiority Trial. Circulation 137 : 1997-2009, 2018.
PubMed
6) Hiro T, et al : Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome : a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54 : 293-302, 2009.
 
7) Mozaffarian D, et al : Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 : 1124-1129, 2004.
PubMed
8) Krum H, et al : Statins and symptomatic chronic systolic heart failure : a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 119 : 48-53, 2007.
PubMed
9) Node K, et al : Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 : 839-843, 2003.
PubMed
10) Kjekshus J, et al : Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 : 2248-2261, 2007.
PubMed
11) Tavazzi L, et al : Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : a randomised, double-blind, placebo-controlled trial. Lancet 372 : 1231-1239, 2008.
 
12) Takano H, et al : Effects of pitavastatin in Japanese patients with chronic heart failure : the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77 : 917-925, 2013.
PubMed
13) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098. 2007.
PubMed
14) Bhatt DL, et al : Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380 : 11-22, 2019.
PubMed
15) Cannon CP, et al : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 : 2387-2397, 2015.
PubMed
16) Tsujita K, et al : Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention : The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 66 : 495-507, 2015.
 
17) Sabatine MS, et al : Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376 : 1713-1722, 2017.
PubMed
P.191 掲載の参考文献
1) Anavekar NS, et al : Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 : 1285-1295, 2004.
PubMed
2) Damman K, et al : Renal impairment, worsening renal function, and outcome in patients with heart failure : an updated meta-analysis. Eur Heart J 35 : 455-469, 2014.
PubMed
3) Kajimoto K, et al : Associations of anemia and renal dysfunction with outcomes among patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction. Clin J Am Soc Nephrol 9 : 1912-1921, 2014.
 
4) Hamaguchi S, et al : Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1442-1447, 2009.
PubMed
5) Schiffrin EL, et al : Chronic kidney disease : effects on the cardiovascular system. Circulation 116 : 85-97, 2007.
PubMed
6) Silverberg D, et al : The cardio-renal anaemia syndrome : does it exist? Nephrol Dial Transplant 18 (Suppl 8) : viii7-12, 2003.
 
7) CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
8) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
9) Vardeny O, et al : Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure : insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60 : 2082-2089, 2012.
PubMed
10) Eschalier R, et al : Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function : analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survlval Study in Heart Failure). J Am Coll Cardiol 62 : 1585-1593, 2013.
PubMed
11) Wali RK, et al : Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease : a meta-analysis of randomized trials. Circ Heart Fail 4 : 18-26, 2011.
PubMed
12) Castagno D, et al : Improved survival with bisoprolol in patients with heart failure and renal impairment : an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 12 : 607-616, 2010.
PubMed
13) Eshaghian S, et al : Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97 : 1759-1764, 2006.
PubMed
14) Cosin J, et al : Torasemide in chronic heart failure : results of the TORIC study. Eur J Heart Fail 4 : 507-513, 2002.
PubMed
15) Anker SD, et al : Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 : 2436-2448, 2009.
PubMed
P.195 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン 第2版 2012年追補ダイジェスト版 (日本痛風・核酸代謝学会ガイドライン改訂委員会編). [http://www.tukaku.jp/wp-content/uploads/2013/06/tufu-GL2.pdf] (2018年12月閲覧)
 
2) Hamaguchi S, et al : Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151 : 143-147, 2011.
PubMed
3) Bergamini C, et al : Oxidative stress and hyperuricaemia : pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11 : 444-452, 2009.
PubMed
4) Roch-Ramel F, et al : Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 280 : 839-845, 1997.
PubMed
5) Cantu-Medellin N, Kelley EE : Xanthine oxidoreductase-catalyzed reactive species generation : A process in critical need of reevaluation. Redox Biol 1 : 353-358, 2013.
PubMed
6) Tamariz L, et al : Uric acid as a predictor of all-cause mortality in heart failure : a meta-analysis. Congest Heart Fail 17 : 25-30, 2011.
PubMed
7) Sautin YY, Johnson RJ : Uric acid : the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27 : 608-619, 2008.
PubMed
8) Ogino K, et al : Uric acid-lowering treatment with benzbromarone in patients with heart failure : a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 3 : 73-81, 2010.
PubMed
9) Landmesser U, et al : Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure : role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106 : 3073-3078, 2002.
PubMed
10) Leyva F, et al : Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18 : 858-865, 1997.
PubMed
11) Hare JM, et al : Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPTCHF study. J Am Coll Cardiol 51 : 2301-2309, 2008.
PubMed
12) Givertz MM, et al : Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients : The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 131 : 1763-1771, 2015.
 
13) Tamariz L, Hare JM : Xanthine oxidase inhibitors in heart failure : where do we go from here? Circulation 131 : 1741-1744, 2015.
PubMed
14) Yokota T, et al : Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF). Int Heart J 59 : 976-982, 2018.
PubMed
P.202 掲載の参考文献
1) 日本呼吸器学会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン, 第4版, メディカルレビュー, 2013.
 
2) Taube C, et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162 : 216-220, 2000.
PubMed
3) Chen W, et al : Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease : a systematic review and meta-analysis. Lancet Respir Med 3 : 631-639, 2015.
PubMed
4) 大西勝也 : 新しいLABAオンブレスによるCOPD治療のパラダイムシフト IV, 循環器専門医からみたオンブレスの有用性. 吸入療法 4 : 46-52, 2012
 
5) Gosker HR, et al : Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure : underlying mechanisms and therapy perspectives. Am J Clin Nutr 71 : 1033-1047, 2000.
PubMed
6) Yoshihisa A, et al : Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 64 : 256-264, 2014.
PubMed
7) Pitta F, et al : Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 : 972-977, 2005.
PubMed
8) Onishi K : Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol 70 : 128-134, 2017.
PubMed
9) Nakamori S, et al : Myocardial perfusion reserve is impaired in patients with chronic obstructive pulmonary disease : a comparison to current smokers. Eur Heart J Cardiovasc Imaging 15 : 180-188, 2014.
PubMed
10) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
11) Tashkin DP, et al : A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 : 1543-1554, 2008.
PubMed
12) Forth R, et al : ACE in COPD : a therapeutic target? Thorax 58 : 556-558, 2003.
PubMed
13) Short PM, et al : Effect of beta blockers in treatment of chronic obstructive pulmonary disease : a retrospective cohort study. BMJ 342 : d2549, 2011.
PubMed
14) Jabbour A, et al : Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease : a randomized crossover trial. J Am Coll Cardiol 55 : 1780-1787, 2010.
PubMed
15) Global Initiative for Asthma : Global Strategy for Asthma Management and Prevention. [http://ginasthma.org/gina-report-global-strategy-for-asthma-management-and-prevention] (2016年2月閲覧)
 
P.207 掲載の参考文献
1) Anand IS, Gupta P : Anernia and Iron Deficiency in Heart Failure : Current Concepts and Emerging Therapies. Circulation 138 : 80-98, 2018.
PubMed
2) Kajimoto K, et al : Association between anemia, clinical features and outcome in patients hospitalized for acute heart failure syndromes. Eur Heart J Acute Cardiovasc Care 4 : 568-576, 2015.
PubMed
3) Yamauchi T, et al : Prognostic Impact of Anemia in Patients With Chronic Heart Failure-With Special Reference to Clinical Background : Report From the CHART-2 Study. Circ J 79 : 1984-1993, 2015.
PubMed
4) Cleland JG, et al : Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiol 1 : 539-547, 2016.
PubMed
5) Cohen-Solal A, et al : High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 16 : 984-991, 2014.
PubMed
6) Klip IT, et al : Iron deficiency in chronic heart failure : an international pooled analysis. Am Heart J 165 : 575-582. e3, 2013.
 
7) Mclntyre L, et al : Blood component transfusion in critically ill patients. Curr Opin Crit Care 19 : 326-333, 2013.
 
8) Swedberg K, et al : Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 : 1210-1219, 2013.
PubMed
9) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
10) Anker SD, et al : Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 : 2436-2448, 2009.
PubMed
11) Ponikowski P, et al : Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 : 657-668, 2015.
PubMed
12) Jankowska EA, et al : Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure : a meta-analysis of randomized controlled trials. Eur J Heart Fail 18 : 786-795, 2016.
PubMed
13) Lewis GD, et al : Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency : The IRONOUT HF Randomized Clinical Trial. JAMA 317 : 1958-1966, 2017.
PubMed
14) Naito Y, et al : Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens 29 : 741-748, 2011.
PubMed
P.213 掲載の参考文献
1) 福田恵一, ほか : 肺高血圧症治療ガイドライン (2017年改訂版). 循環器病の診断と治療に関するガイドライン, 2018.
 
2) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 : 67-119, 2016.
 
3) Simonneau G, et al : Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 : D34-41, 2013.
PubMed
4) Machado RD, et al : Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 54 : S32-42, 2009.
PubMed
5) Harrison RE, et al : Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40 : 865-871, 2003.
PubMed
6) Montani D, et al : Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125 : 2128-2137, 2012.
PubMed
7) Humbert M, et al : Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122 : 156-163, 2010.
PubMed
8) Tyndall AJ, et al : Causes and risk factors for death in systemic sclerosis : a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 : 1809-1815, 2010.
PubMed
9) Humbert M, et al : Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 130 : 2189-2208, 2014.
PubMed
10) Domenighetti G : Prognosis, screening, early detection and differentiation of arterial pulmonary hypertension. Swiss Med Wkly 137 : 331-336, 2007.
PubMed
11) D'Alonzo GE, et al : Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 : 343-349, 1991.
 
P.221 掲載の参考文献
1) Kataoka M, et al : Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5 : 756-762, 2012.
PubMed
2) Andreassen AK, et al : Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 99 : 1415-1420, 2013.
PubMed
3) 内藤貴教, ほか : BPA治療の最前線 : 最先端の治療の変遷と最近のトピックス (特集 末梢血管疾患インターベンション (EVT) の最前線). 循環器内科 80 : 486-492, 2016.
 
4) Riedel M, et al : Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81 : 151-158, 1982.
PubMed
5) Pengo V, et al : Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 : 2257-2264, 2004.
PubMed
6) Lang IM, et al : Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension : acurrent understanding. Eur Respir J 41 : 462-468, 2013.
 
7) 日本循環器学会, ほか : 肺高血圧症治療ガイドライン (2017年改訂版) ; Guidelines for Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017), P68-69, 2018.
 
8) Ogino H : Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. In : Diagnosis and Treatment of Pulmonary Hypertension : from Bench to Bedside (ed by Fukumoto Y), p203-214, Springer, Singapore, 2017.
 
9) Freed DH, et al : Survival after pulmonary thromboendarterectomy : effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg 141 : 383-387, 2011.
PubMed
10) Feinstein JA, et al : Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 103 : 10-13, 2001.
PubMed
11) Mizoguchi H, et al : Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5 : 748-755, 2012.
PubMed
12) 日本循環器学会, ほか : 2014年版慢性肺動脈血栓塞栓症に対するBalloon pulmonary angioplastyの適応と実施法に関するステートメント (2011-2013年度合同研究班報告), 2014.
 
13) Ghofrani HA, et al : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369 : 319-329, 2013.
PubMed
14) Naito T, et al : Ages are not a determinant of favorable outcome of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Heart J 39 (Issue Suppl 1) : 2615, 2018.
 
P.227 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告) 循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン. Circ J 74 (Suppl II) : 963-1052, 2010.
 
2) Kasai T : Sleep apnea and heart failure. J Cardiol 60 : 78-85, 2012.
PubMed
3) Kasai T, Bradley TD : Obstructive sleep apnea and heart failure : pathophysiologic and therapeutic implications. J Am Coll Cardiol 57 : 119-127, 2011.
PubMed
4) Kasai T, et al : Sleep apnea and cardiovascular disease : a bidirectional relationship. Circulation 126 : 1495-1510, 2012.
PubMed
5) Lyons OD, et al : Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea : the ADVENT-HF trial. Eur J Heart Fail 19 : 579-587, 2017.
 
6) 日本循環器学会/日本心不全学会合同ガイドライン急性・慢性心不全診療ガイドライン (2017年改訂版) Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure (JCS 2017/JHFS 2017), 2018.
 
7) Selim BJ, Ramar K : Management of Sleep Apnea Syndromes in Heart Failure. Sleep Med Clin 12 : 107-121, 2017.
PubMed
8) Murase K, et al : Adaptive servoventilation versus oxygen therapy for sleep disordered breathing in patients with heart failure : a randomised trial. Open Heart 3 : e000366, 2016.
PubMed
9) Kato T, et al : Positive airway pressure therapy for heart failure. World J Cardiol 6 : 1175-1191, 2014.
PubMed
10) Bradley TD, et al : Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 : 2025-2033, 2005.
PubMed
11) Arzt M, et al : Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure : a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 115 : 3173-3180, 2007.
PubMed
12) Tomita Y, Kasai T : Effectiveness of adaptive servo-ventilation. World J Respirol 5 : 112-125, 2015.
 
13) Momomura S, et al : Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J 79 : 981-990, 2015.
 
14) Cowie MR, et al : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 373 : 1095-1105, 2015.
PubMed
15) O'Connor CM, et al : Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure : The CAT-HF Trial. J Am Coll Cardiol 69 : 1577-1587, 2017.
 
P.232 掲載の参考文献
1) Rutledge T, et al : Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48 : 1527-1537, 2006.
PubMed
2) Easton K, et al : Prevalence and Measurement of Anxiety in Samples of Patients With Heart Failure : Meta-analysis. J Cardiovasc Nurs 31 : 367-379, 2016.
PubMed
3) Gathright EC, et al : Depression increases the risk of mortality in patients with heart failure : A meta-analysis. J Psychosom Res 94 : 82-89, 2017.
PubMed
4) Sokoreli I, et al : Depression and anxiety as predictors of mortality among heart failure patients : systematic review and meta-analysis. Heart Fail Rev 21 : 49-63, 2016.
PubMed
5) Suzuki T, et al : Impact of clustered depression and anxiety on mortality and rehospitalization in patients with heart failure. J Cardiol 64 : 456-462, 2014.
PubMed
6) Moser DK, et al : Psychological Aspects of Heart Failure. Curr Cardiol Rep 18 : 119, 2016.
PubMed
7) Magyar-Russell G, et al : The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators : a systematic review. J Psychosom Res 71 : 223-231, 2011.
PubMed
8) Kobayashi S, et al : Post-traumatic stress disorder and its risk factors in Japanese patients living with implantable cardioverter defibrillators : Apreliminary examination. J Arrhythm 30 : 105-110, 2014.
 
9) Lichtman JH, et al : Depression and coronary heart disease : recommendations for screening, referral, and treatment : a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research : endorsed by the American Psychiatric Association. Circulation 118 : 1768-1775, 2008.
PubMed
10) O'Connor CM, et al : Safety and efficacy of sertraline for depression in patients with heart failure : results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 56 : 692-699, 2010.
 
11) Kuchibhatla MN, Fillenbaum GG : Trajectory classes of depression in a randomized depression trial of heart failure patients : a reanalysis of the SADHART-CHF trial. Am J Geriatr Pharmacother 9 : 483-494, 2011.
 
12) Angermann CE, et al : Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression : The MOOD-HF Randomized Clinical Trial. JAMA 315 : 2683-2693, 2016.
PubMed
13) Jeyanantham K, et al : Effects of cognitive behavioural therapy for depression in heart failure patients : a systematic review and meta-analysis. Heart Fail Rev 22 : 731-741, 2017.
PubMed
14) Tu RH, et al : Effects of exercise training on depression in patients with heart failure : a systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail 16 : 749-757, 2014.
PubMed
15) Bekelman DB, et al : Effect of a Collaborative Care Intervention vs Usual Care on Health Status of Patients With Chronic Heart Failure : The CASA Randomized Clinical Trial. JAMA Intern Med 178 : 511-519, 2018.
PubMed
P.237 掲載の参考文献
1) Divani AA, et al : Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail 15 : 11-16, 2009.
PubMed
2) Ois A, et al : Heart failure in acute ischemic stroke. J Neurol 255 : 385-389, 2008.
PubMed
3) Hays AG, et al : Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 37 : 1715-1719, 2006.
 
4) Broderick J, et al : The Greater Cincinnati/Northern Kentucky Stroke Study : preliminary first-ever and total incidence rates of stroke among blacks. Stroke 29 : 415-421, 1998.
PubMed
5) Al-Khadra AS, et al : Antiplatelet agents and survival : a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 31 : 419-425, 1998.
 
6) CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
7) Witt BJ, et al : Ischemic stroke after heart failure : a community-based study. Am Heart J 152 : 102-109, 2006.
PubMed
8) Vemmos K, et al : Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke : a 10-year follow-up study. Eur J Heart Fail 14 : 211-218, 2012.
PubMed
9) Melgaard L, et al : Risk of stroke and bleeding in patients with heart failure and chronic kidney disease : a nationwide cohort study. ESC Heart Fail 5 : 319-326, 2018.
PubMed
10) Adelborg K, et al : Risk of Stroke in Patients With Heart Failure : A Population-Based 30-Year Cohort Study. Stroke 48 : 1161-1168, 2017.
PubMed
11) Kang SH, et al : Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol 248 : 182-187, 2017.
PubMed
12) Shantsila E, Lip GY : Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Cochrane Database Syst Rev 9 : CDOO3333, 2016. (doi : 10.1002/14651858.CD003333.pub3)
 
13) Massie BM, et al : Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure : the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119 : 1616-1624, 2009.
PubMed
14) Abdul-Rahim AH, et al : Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation : analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J 38 : 742-750, 2017.
PubMed
15) Abdul-Rahim AH, et al : Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation : Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nelrInsufficienza Cardiaca-Heart Failure (GISSIHF) Trials. Circulation 131 : 1486-1494 ; discussion 1494, 2015.
PubMed
16) Sandhu RK, et al : Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke 46 : 667-672, 2015.
PubMed
17) Kotecha D, et al : Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction : A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 203 : 660-666, 2016.
PubMed
18) Hamatani Y, et al : Elevated Plasma D-Dimer Level Is Associated With Short-Term Risk of Ischemic Stroke in Patients With Acute Heart Failure. Stroke 49 : 1737-1740, 2018.
PubMed
19) Kozdag G, et al : Silent cerebral infarction in chronic heart failure : ischemic and nonischemic dilated cardiomyopathy. Vasc Health Risk Manag 4 : 463-469, 2008.
PubMed
20) Siachos T, et al : Silent strokes in patients with heart failure. J Card Fail 11 : 485-489, 2005.
PubMed
21) Vogels RL, et al : Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 9 : 1003-1009, 2007.
PubMed
22) Vermeer SE, et al : Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 33 : 21-25, 2002.
PubMed
23) Melgaard L, et al : Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA 314 : 1030-1038, 2015.
PubMed
24) Di Tullio MR, et al : Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure : Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. Stroke 47 : 2031-2037, 2016.
PubMed
25) Freudenberger RS, et al : The first prognostic model for stroke and death in patients with systolic heart failure. J Cardiol 68 : 100-103, 2016.
PubMed
26) Ferreira Jp, et al : Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. J Am Coll Cardiol 71 : 727-735, 2018.
PubMed
27) Xiong Q, et al : Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure : asystemic review and meta-analysis of randomized trials. Eur J Heart Fail 17 : 1192-1200, 2015.
 
28) Zannad F, et al : Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med 379 : 1332-1342, 2018.
PubMed
P.243 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
2) Fukuta H, et al : The effect of influenza vaccination on mortality and hospitalization in patients with heart failure : a systematic review and meta-analysis. Heart Fail Rev 24 : 109-114, 2019.
PubMed
3) American Heart Association : Get With The Guidelines-Heart Failure. [http://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-heart-failure] (2019年4月閲覧)
 
4) Modin D, et al : Influenza vaccine in Heart failure. Circulation 139 : 575-586, 2019.
PubMed
5) Ackerson B, et al : Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. Clin Infect Dis, 2018. [Epub ahead of print]
 
6) Fountoulaki K, et al : Beneficial Effects of Vaccination on Cardiovascular Events : Myocardial Infarction, Stroke, Heart Failure. Cardiology 141 : 98-106, 2018.
PubMed
7) Beesley SJ, et al : Septic Cardiomyopathy. Crit Care Med 46 : 625-634, 2018.
PubMed
8) Sato R, et al : Prevalence and risk factors of sepsis-induced cardiomyopathy : A retrospective cohort study. Medicine (Baltimore) 95 : e5031, 2016.
PubMed
9) National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001. Am J Infect Control 29 : 404-421, 2001.
PubMed
10) CDC : Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011.
 
11) Pereda D, Conte JV : Left ventricular assist device driveline infections. Cardiol Clin 29 : 515-527, 2011.
PubMed
12) 日本循環器学会/日本心臓血管外科学会合同ガイドライン (2011-2012年度合同研究班報告). 重症心不全に対する植込型補助人工心臓治療ガイドライン, 2014.
 
13) Simeon S, et al : Left ventricular assist device-related infections : a multicentric study. Clin Microbiol Infect 23 : 748-751, 2017.
PubMed
14) Moazami N, et al : Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg 95 : 500-505, 2013.
PubMed
15) Anand J, et al : Continuous-flow ventricular assist device exchange is safe and effective in prolonging support time in patients with end-stage heart failure. J Thorac Cardiovasc Surg 149 : 267-275, 278. el. 2015.
 

XXI 心不全の原因疾患 ( 基礎疾患 ) - 病態, 発症機序 ( 心不全 ), 治療 -

P.251 掲載の参考文献
1) Maron BJ, et al : Contemporary definitions and classification of the cardiomyopathies : an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee ; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups ; and Council on Epidemiology and Prevention. Circulation 113 : 1807-1816, 2006.
PubMed
2) Elliott P, et al : Classification of the cardiomyopathies : a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 : 270-276, 2008.
 
3) Ambrosy AP, et al : The global health and economic burden of hospitalizations for heart failure : lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63 : 1123-1133, 2014.
PubMed
4) Kjekshus J, et al : Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 : 2248-2261, 2007.
PubMed
5) Tavazzi L, et al : Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : a randomised, double-blind, placebo-controlled trial. Lancet 372 : 1231-1239, 2008.
 
6) Velazquez EJ, et al : Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364 : 1607-1616, 2011.
PubMed
7) Mark DB, et al : Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction : a randomized trial. Ann Intern Med 161 : 392-399, 2014.
PubMed
8) Velazquez EJ, et al : Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 374 : 1511-1520, 2016.
PubMed
9) Bangalore S, et al : Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction : Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. Circulation 133 : 2132-2140, 2016.
PubMed
10) Jones RH, et al : Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 360 : 1705-1717, 2009.
 
P.257 掲載の参考文献
1) Kajimoto K, et al : Relation of left ventricular ejection fraction and clinical features or co-morbidities to outcomes among patients hospitalized for acute heart failure syndromes. Am J Cardiol 115 : 334-340, 2015.
PubMed
2) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan--first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
3) Shiba N, et al : Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction-comparison with nonischemic cardiomyopathy. Circ J 69 : 143-149, 2005.
PubMed
4) Kajimoto K, et al : Etiology of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction. Am J Cardiol 118 : 1881-1887, 2016.
 
5) Allman KC, et al : Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction : a meta-analysis. J Am Coll Cardiol 39 : 1151-1158, 2002.
PubMed
6) Myers WO, et al : CASS Registry long term surgical survival. Coronary Artery Surgery Study. J Am Coll Cardiol 33 : 488-498, 1999.
PubMed
7) Velazquez EJ, et al : Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 374 : 1511-1520, 2016.
PubMed
8) 落雅美, ほか : 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) 虚血性心疾患に対するバイパスグラフトと手術術式の選択ガイドライン (2011年改訂版). [http://www.jcirc.or.jp/guideline/pdf/JCS2011_ochi_h.pdf] (2019年4月閲覧)
 
9) Jones RH, et al : Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 360 : 1705-1717, 2009.
 
10) Deja MA, et al : Infiuence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 125 : 2639-2648, 2012.
 
11) Mohr FW, et al : Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381 : 629-638, 2013.
PubMed
12) Stone GW, et al : Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med 375 : 2223-2235, 2016.
 
13) Marui A, et al : Three-year outcomes after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure : from the CREDO-Kyoto percutaneous coronary intervention/coronary artery bypass graft registry cohort-2. Eur J Cardiothorac Surg 47 : 316-321 ; discussion 321, 2015.
PubMed
14) Bangalore S, et al : Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction : Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. Circulation 133 : 2132-2140, 2016.
PubMed
15) Nagendran J, et al : Coronary revascularization for patients with severe left ventricular dysfunction. Ann Thorac Surg 96 : 2038-2044, 2013.
PubMed
P.264 掲載の参考文献
1) 日本循環器病学会, ほか : 循環器病の診断と治療に関するガイドライン 2011 : 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン. [http://www.j-circ.or.jp/guideline/pdf/JCS2011_tomoike_h.pdf] (2019年2月閲覧)
 
2) Weintraub RG, et al : Dilated cardiomyopathy. Lancet 390 : 400-414, 2017.
PubMed
3) Mestroni L, et al : Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 20 : 93-102, 1999.
 
4) Herman DS, et al : Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366 : 619-628, 2012.
PubMed
5) Perez-Serra A, et al : A novel mutation in lamin a/c causing familial dilated cardiomyopathy associated with sudden cardiac death. J Card Fail 21 : 217-225, 2015.
PubMed
6) Al-Khatib SM, et al : 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 72 : e91-e220, 2018.
 
7) Tobita T, et al : Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 8 : 1998, 2018. (doi : 10.1038/s41598-018-20114-9)
 
8) Merlo M, et al : Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 57 : 1468-1476, 2011.
PubMed
9) Gulati A, et al : The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation 128 : 1623-1633, 2013.
PubMed
10) Rossi A, et al : Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of l256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97 : 1675-1680, 2011.
 
11) Kawata T, et al : Echocardiographic assessment of right ventricular function in routine practice : Which parameters are useful to predict one-year outcome in advanced heart failure patients with dilated cardiomyopathy? J Cardiol 70 : 316-322, 2017.
PubMed
12) Assomull RG, et al : Cardiovascular magnetic resonance. fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 : 1977-1985, 2006.
PubMed
13) Obadia JF, et al : Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379 : 2297-2306, 2018.
 
14) Stone GW, et al : Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
15) 日本循環器学会, ほか : 2016年版 心臓移植に関する提言. [http://www.j-circ.or.jp/gUideline/pdf/JCS2016_isobe_h.pdf] (2019年2月閲覧)
 
P.270 掲載の参考文献
1) 心筋症診療ガイドライン (2018年改訂版). 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). [http://www.j-circ.or.jp/guideline/pdf/JCS2018_tsutsui_kitaoka.pdf] (2019年4月閲覧)
 
2) Maron BJ : Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 379 : 655-668, 2018.
PubMed
3) Gersh BJ, et al : 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Am Coll Cardiolol 58 : 2703-2738, 2011.
PubMed
4) Authors/Task Force members, et al : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy : the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 : 2733-2779. 2014.
 
5) Olivotto I, et al : Patterns of disease progression in hypertrophic cardiomyopathy : an individualized approach to clinical staging. Circ Heart Fail 5 : 535-546, 2012.
PubMed
6) Guttmann OP, et al : Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 17 : 837-845, 2015.
PubMed
7) Rowin EJ, et al : Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 136 : 2420-2436, 2017.
PubMed
8) Coats CJ, et al : Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Heart Fail 8 : 1022-1031, 2015.
PubMed
9) Rowin EJ, et al : Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging 10 : 1374-1386, 2017.
PubMed
10) Maron BJ, et al : Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail 6 : 353-363, 2018.
PubMed
11) Sherrid MV, et al : The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy : A Test in Context. J Am Coll Cardiol 67 : 1846-1858, 2016.
PubMed
12) Kitaoka H, et al : Left ventricular remodeling of hypertrophic cardiomyopathy : longitudinal observation in rural community. Circ J 70 : 1543-1549, 2006.
PubMed
13) 北岡裕章 : 拡張障害からみた心筋症. 心臓 51 : 227-233, 2019.
Medical*Online
14) 2014年版 先天性心疾患, 心臓大血管の構造的疾患 (structural heart disease) に対するカテーテル治療のガイドライン. 2012～2013年度合同研究班報告. [http://www.j-circ.or.jp/guideline/pdf/JCS2014_nakanishi_h.pdf] (2019年1月閲覧)
 
P.274 掲載の参考文献
1) 難病情報センター/拘束型心筋症 (指定難病 59). [http://www.nanbyou.or.jp/] (2019年1月閲覧)
 
2) Ammash NM, Tajik AJ : Idiopathic restrictive cardiomyopathy. Up To Date. Wolters Kluwer.
 
3) Kushwaha SS, et al : Restrictive cardiomyopathy. N Engl J Med 336 : 267-276, 1997.
PubMed
4) Ammash NM, et al : Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101 : 2490-2496, 2000.
PubMed
5) Wu W, et al : Novel Phenotype-Genotype Correlations of Restrictive Cardiomyopathy With Myosin-Binding Protein C (MYBPC3) Gene Mutations Tested by Next-Generation Sequencing. J Am Heart Assoc 4 : 2015.
 
6) Nagueh SF, et al : Recommendations for the Evaiuation of Left Ventricular Diastolic Function by Echocardiography : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 : 277-314, 2016.
PubMed
7) Rajagopalan N, et al : Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 87 : 86-94, 2001.
PubMed
8) Amaki M, et al : Diagnostic concordance of echocardiography and cardiac magnetic resonance-based tissue tracking for differentiating constrictive pericarditis from restrictive cardiomyopathy. Circ Cardiovasc Imaging 7 : 819-827, 2014.
PubMed
9) Leya FS, et al : The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45 : 1900-1902, 2005.
PubMed
P.280 掲載の参考文献
1) Fontaine G, et al : Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathies. In : Cardiac electrophysiology ; From Cell to Bedside, 4th ed, p588-600, WB Saunders, Philadephia, 2004.
 
2) Richardson P, et al : Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 : 841-842, 1996.
PubMed
3) Mallat Z, et al : Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med 335 : 1190-1196, 1996.
PubMed
4) Basso C, et al : Arrhythmogenic right ventricular cardiomyopathy. Lancet 373 : 1289-1300, 2009.
PubMed
5) Hodgkinson KA, et al : The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 45 : 400-408, 2005.
 
6) Rigato I, et al : Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 6 : 533-542, 2013.
PubMed
7) Kimura Y, et al : Potentially Lethal Ventricular Arrhythmias and Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy : What Are the Differences Between Men and Women? JACC Clin Electrophysiol 2 : 546-555, 2016.
PubMed
8) Corrado D, et al : Arrhythmogenic right ventricular dysplasia/cardiomyopathy : need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 101 : E101-106, 2000.
 
9) Ott P, et al : Cardiac sarcoidosis masquerading as right ventricular dysplasia. Pacing Clin Electrophysiol 26 : 1498-1503, 2003.
PubMed
10) Corrado D, et al : Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia : a multicenter study. J Am Coll Cardiol 30 : 1512-1520, 1997.
PubMed
11) Basso C, Thiene G : Adipositas cordis, fatty infiltration of the right ventricle, and arrhythmogenic right ventricular cardiomyopathy. Just a matter of fat? Cardiovasc Pathol 14 : 37-41, 2005.
PubMed
12) Basso C, et al : Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia : an in vitro validation of diagnostic criteria. Eur Heart J 29 : 2760-2771, 2008.
 
13) Marcus FI, et al : Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia : proposed modification of the task force criteria. Circulation 121 : 1533-1541, 2010.
PubMed
14) Protonotarios N, Tsatsopoulou A : Naxos disease and Carvajal syndrome : cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol 13 : 185-194, 2004.
PubMed
15) Gomes J, et al : Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. Eur Heart J 33 : 1942-1953, 2012.
PubMed
16) Bauce B, et al : Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 85 : 573-579, 2000.
PubMed
17) Norgett EE, et al : Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 9 : 2761-2766, 2000.
PubMed
18) Tiso N, et al : Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 10 : 189-194, 2001.
PubMed
19) Basso C, et al : Arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 5 : 1233-1246, 2012.
PubMed
20) Wada Y, et al : Unique genetic background and outcome of non-Caucasian Japanese probands with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Mol Genet Genomic Med 5 : 639-651, 2017.
PubMed
21) Kapplinger JD, et al : Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol 57 : 2317-2327, 2011.
PubMed
22) Wichter T, et al : Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 86 : 29-37, 1992.
PubMed
23) Marcus GM, et al : Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy : a report from the North American ARVC Registry. J Am Coll Cardiol 54 : 609-615, 2009.
PubMed
24) Bhonsale A, et al : Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 58 : 1485-1496, 2011.
PubMed
25) Corrado D, et al : Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia : An International Task Force Consensus Statement. Circulation 132 : 441-453, 2015.
PubMed
26) Corrado D, et al : Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 122 : 1144-1152, 2010.
PubMed
27) Dalal D, et al : Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 50 : 432-440, 2007.
PubMed
28) Nogami A, et al : Changes in the isolated delayed component as an endpoint of catheter ablation in arrhythmogenic right ventricular cardiomyopathy : predictor for long-term success. J Cardiovasc Electrophysiol 19 : 681-688, 2008.
 
29) Kimura Y, et al : Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy : What are the risk factors? Int J Cardiol 241 : 288-294, 2017.
PubMed
P.288 掲載の参考文献
1) Kovacevic-Preradovic T, et al : Isolated left ventricular noncompaction as a cause for heart failure and heart transplantation : a single center experience. Cardiology 112 : 158-164, 2009.
PubMed
2) Kovacevic-Preradovic T, et al : Isolated left ventricular noncompaction as a cause for heart failure and heart transplantation : a single center experience. Cardiology 112 : 158-164, 2009.
PubMed
3) Ichida F, et al : Clinical features of isolated noncompaction of the ventricular myocardium : long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol 34 : 233-240, 1999.
PubMed
4) Jefferies JL, et al : Cardiomyopathy Phenotypes and Outcomes for Children With Left Ventricular Myocardial Noncompaction : Results From the Pediatric Cardiomyopathy Registry. J Card Fail 21 : 877-884, 2015.
PubMed
5) Ichida F : Left ventricular noncompaction. Circ J 73 : 19-26, 2009.
 
6) Wang C, et al : Long-Term Prognosis of Patients With Left Ventricular Noncompaction-Comparison Between Infantile and Juvenile Types. Circ J 81 : 694-700, 2017.
 
7) Wang C, et al : A Wide and Specific Spectrum of Genetic Variants and Genotype-Phenotype Correlations Revealed by Next-Generation Sequencing in Patients with Left Ventricular Noncompaction. J Am Heart Assoc 6 : e006210, 2017. (doi : 10.1161/JAHA.117.006210)
 
8) Gati S, et al : Adult left ventricular noncompaction : reappraisal of current diagnostic imaging modalities. JACC Cardiovasc Imaging 7 : 1266-1275, 2014.
PubMed
9) Kohli SK, et al : Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction : time for a reappraisal of diagnostic criteria? Eur Heart J 29 : 89-95, 2008.
PubMed
10) Hirono K, et al : Familial Ebstein's anomaly, left ventricular noncompaction, and ventricular septal defect associated with an MYH7 mutation. J Thorac Cardiovasc Surg 148 : e223-226, 2014.
PubMed
11) Postma AV, et al : Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet 4 : 43-50, 2011.
PubMed
12) Cetin MS, et al : Usefulness of Fragmented QRS Complex to Predict Arrhythmic Events and Cardiovascular Mortality in Patients With Noncompaction Cardiomyopathy. Am J Cardiol 117 : 1516-1523, 2016.
PubMed
13) Li S, et al : Genotype-Positive Status Is Associated With Poor Prognoses in Patients With Left Ventricular Noncompaction Cardiomyopathy. J Am Heart Assoc 7 : e009910, 2018.
PubMed
14) Takasaki A, et al : Sarcomere gene variants act as a genetic trigger underlying the development of left ventricular noncompaction. Pediatr Res 84 : 733-742, 2018.
PubMed
15) Saito K, et al : Successful cardiac resynchronization therapy in a 3-year-old girl with isolated left ventricular non-compaction and narrow QRS complex : a case report. Circ J 73 : 2173-2177, 2009.
 
P.295 掲載の参考文献
1) Akashi YJ, et al : Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol 12 : 387-397, 2015.
PubMed
2) Lyon AR, et al : Current state of knowledge on Takotsubo syndrome : a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 18 : 8-27, 2016.
 
3) Ghadri JR, et al : Long-Term Prognosis of Patients With Takotsubo Syndrome. J Am Coll Cardiol 72 : 874-882, 2018.
PubMed
4) Akashi YJ, et al : Takotsubo cardiomyopathy : a new form of acute, reversible heart failure. Circulation 118 : 2754-2762, 2008.
PubMed
5) Deshmukh A, et al : Prevalence of Takotsubo cardiomyopathy in the United States. Am Heart J 164 : 66-71. e1, 2012.
 
6) Ghadri JR, et al : International Expert Consensus Document on Takotsubo Syndrome (Part I) : Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J 39 : 2032-2046, 2018.
PubMed
7) Ghadri JR, et al : Happy heart syndrome : role of positive emotional stress in takotsubo syndrome. Eur Heart J 37 : 2823-2829, 2016.
PubMed
8) Templin C, et al : Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med 373 : 929-938, 2015.
PubMed
9) Randhawa MS, et al : Diagnostic utility of cardiac biomarkers in discriminating Takotsubo cardiomyopathy from acute myocardial infarction. J Card Fail 20 : 377. e25-31, 2014.
 
10) Wittstein IS, et al : Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352 : 539-548, 2005.
PubMed
11) Akashi YJ, et al : Reversible ventricular dysfunction takotsubo cardiomyopathy. Eur J Heart Fail 7 : 1171-1176, 2005.
PubMed
12) Kosuge M, et al : Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. J Am Coll Cardiol 55 : 2514-2516, 2010.
PubMed
13) Kosuge M, et al : Differences in negative T waves between takotsubo cardiomyopathy and reperfused anterior acute myocardial infarction. Circ J 76 : 462-468, 2012.
PubMed
14) Isogai T, et al : Clinical characteristics of patients with Takotsubo syndrome diagnosed without coronary artery evaluation : A retrospective nationwide study. J Cardiol 71 : 268-276, 2018.
PubMed
15) Pathik B, et al : Troponin-positive chest pain with unobstructed coronary arteries : incremental diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 17 : 1146-1152, 2016.
PubMed
16) Eitel I, et al : Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 306 : 277-286, 2011.
PubMed
17) Hasbak P, et al : Preserved myocardial blood flow in the apical region involved in takotsubo cardiomyopathy by quantitative cardiac PET assessment. J Nucl Cardiol 19 : 169-171, 2012.
 
18) Akashi YJ, et al : 123I-MIBG myocardial scintigraphy in patients with "takotsubo" cardiomyopathy. J Nucl Med 45 : 1121-1127, 2004.
PubMed
19) Burgdorf C, et al : Regional alterations in myocardial sympathetic innervation in patients with transient left-ventricular apical ballooning (Tako-Tsubo cardiomyopathy). J Nucl Cardiol 15 : 65-72, 2008.
PubMed
20) Christensen TE, et al : (123) I-MIBG Scintigraphy in the Subacute State of Takotsubo Cardiomyopathy. JACC Cardiovasc Imaging 9 : 982-990, 2016.
PubMed
21) Singh K, et al : Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. Int J Cardiol 174 : 696-701, 2014.
PubMed
22) Palla AR, et al : Pretreatment with low-dose β-adrenergic antagonist therapy does not affect severity of Takotsubo cardiomyopathy. Clin Cardiol 35 : 478-481, 2012.
 
23) Isogai T, et al : Early β-blocker use and in-hospital mortality in patients with Takotsubo cardiomyopathy. Heart 102 : 1029-1035, 2016.
 
24) Isogai T, et al : Out-of-hospital versus in-hospital Takotsubo cardiomyopathy : analysis of 3719 patients in the Diagnosis Procedure Combination database in Japan. Int J Cardiol 176 : 413-417, 2014.
PubMed
25) Stiermaier T, et al : Prognostic Usefulness of the Ballooning Pattern in Patients With Takotsubo Cardiomyopathy. Am J Cardiol 118 : 1737-1741, 2016.
PubMed
26) Kagiyama N, et al : Impact of right ventricular involvement on the prognosis of takotsubo cardiomyopathy. Eur Heart J Cardiovasc Imaging 17 : 210-216, 2016.
PubMed
27) Ghadri JR, et al : International Expert Consensus Document on Takotsubo Syndrome (Part II) : Diagnostic Workup, Outcome, and Managelnent. Eur Heart J 39 : 2047-2062, 2018.
PubMed
28) Prasad A, et al : Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy) : a mimic of acute myocardial infarction. Am Heart J 155 : 408-417, 2008.
 
P.300 掲載の参考文献
1) Nerheim P, et al : Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia Circulation 110 : 247-252, 2004.
PubMed
2) Gopinathannair R, et al : Tachycardia-mediated cardiomyopathy : recognition and management. Curr Heart Fail Rep 6 : 257-264, 2009.
PubMed
3) Gupta S, Figueredo VM : Tachycardia mediated cardiomyopathy : pathophysiology, mechanisms, clinical features and management. Int J Cardiol 172 : 40-46, 2014.
PubMed
4) Nakano Y, et al : HCN4 Gene Polymorphisms Are Associated With Occurrence of Tachycardia-Induced Cardiomyopathy in Patients With Atrial Fibrillation. Circ Genom Precis Med 11 : e001980, 2018.
PubMed
5) Jeong YH, et al : Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 31 : 172-178, 2008.
PubMed
6) Ju W, et al : Tachycardiomyopathy complicated by focal atrial tachycardia : incidence, risk factors, and long-term outcome. J Cardiovasc Electrophysiol 25 : 953-957, 2014.
PubMed
7) Yokokawa M, et al : Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm 10 : 172-175, 2013.
PubMed
8) Kusunose K, et al : Clinical utility of longitudinal strain to predict functional recovery in patients with tachyarrhythmia and reduced LVEF. JACC Cardiovasc Imaging 10 : 118-126, 2017.
PubMed
9) Ling LH, et al : Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm 10 : 1334-1339, 2013.
PubMed
10) Ling LH, et al : Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 6 : 697-704, 2013.
PubMed
11) Mueller KAL, et al : Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy. J Am Coll Cardiol 69 : 2160-2172, 2017.
PubMed
12) Gopinathannair R, et al : Arrhythmia-Induced Cardiomyopathies : Mechanisms, Recognition, and Management. J Am Coll Cardiol 66 : 1714-1728, 2015.
PubMed
13) Deshmukh PM, et al : Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 13 : 455-458, 2004.
PubMed
14) Ellinor PT, et al : Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 44 : 670-675, 2012.
PubMed
15) Marrouche NF, et al : Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 378 : 417-427, 2018.
PubMed
16) Sairaku A, et al : Incomplete cure of tachycardia-induced cardiomyopathy secondary to rapid atrial fibrillation by heart rate control without sinus conversion. J Cardiovasc Electrophysiol 25 : 1037-1043, 2014.
PubMed
P.309 掲載の参考文献
1) Birnie DH, et al : Cardiac Sarcoidosis. J Am Coll Cardiol 68 : 411-421, 2016.
PubMed
2) Birnie DH, et al : HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 : 1305-1323, 2014.
PubMed
3) Kandolin R, et al : Cardiac sarcoidosis : epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131 : 624-632, 2015.
 
4) Al-Kindi SG, Oliveira GH : Letter by Al-Kindi and Oliveira regarding article "cardiac sarcoidosis : epidemiology, characteristics, and outcome over 25 years in a nationwide study". Circulation 132 : e211, 2015.
 
5) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシスの診断基準と診断の手引き-2015 (Diagnostic Standard and Guideline for Sarcoidosis-2015). [http://www.jssog.com/www/top/shindan/shindan2-1new.html] (2019年4月閲覧)
 
6) 四十坊典晴, ほか : 類上皮細胞肉芽腫を証明したサルコイドーシス516例における各種検査所見の解析. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 27 : 29-35, 2007.
 
7) Roberts WC, et al : Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 63 : 86-108, 1977.
 
8) 日本心臓核医学会 : 心臓サルコイドーシスに対する18F-FDG PET検査の手引き 2018年改訂. [https://doi.org/10.14951/jsnc.21-001] (2019年4月閲覧)
 
9) Youssef G, et al : The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis : a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53 : 241-248, 2012.
PubMed
10) 日本サルコイドーシス/肉芽腫性疾患学会, ほか : サルコイドーシス診断基準改訂委員会 : サルコイドーシスの診断基準と診断の手引き-2006. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 27 : 89-102, 2007.
 
11) 日本循環器学会, ほか : 2016年版 心臓サルコイドーシスの診療ガイドライン (班長 : 寺崎文生), 2017年2月24日発行 [http://www.j-circ.or.jp/guideline/pdf/JCS2016_terasaki_h.pdf] (2019年4月閲覧)
 
12) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシス診療の手引き 2018. [http://jssog.com/www/top/kenkai20118.html] (2019年4月閲覧)
 
13) 日本サルコイドーシス/肉芽腫性疾患学会, ほか : サルコイドーシス治療ガイドライン策定委員会 : サルコイドーシス治療に関する見解-2003. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 23 : 105-114, 2003.
 
14) 加藤靖周, 森本紳一郎 : サルコイドーシス心病変の診断と治療. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 28 : 15-24, 2008.
 
15) Yazaki Y, et al : Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 : 1006-1010, 2001.
PubMed
16) 日本循環器学会, ほか : 不整脈の非薬物治療ガイドライン (2011年改訂版) (班長 : 奥村謙). [http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf] (2019年4月閲覧)
 
17) Chiu CZ, et al : Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 95 : 143-146, 2005.
PubMed
P.315 掲載の参考文献
1) Falk RH : Diagnosis and management of the cardiac amyloidoses. Circulation 112 : 2047-2060, 2005.
PubMed
2) Falk RH : Cardiac amyloidosis : a treatable disease, often overlooked. Circulation 124 : 1079-1085, 2011.
PubMed
3) Falk RH, et al : The systemic amyloidoses. N Engl J Med 337 : 898-909, 1997.
PubMed
4) Gillmore JD, et al : Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 133 : 2404-2412, 2016.
PubMed
5) Klein AL, et al : Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 13 : 1017-1026, 1989.
PubMed
6) Klein AL, et al : Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16 : 1135-1141, 1990.
PubMed
7) Klein AL, et al : Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 83 : 808-816, 1991.
PubMed
8) Koyama J, et al : Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 89 : 1067-1071, 2002.
PubMed
9) Buss SJ, et al : Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis : incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 60 : 1067-1076, 2012.
PubMed
10) Liu D, et al : Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 6 : 1066-1072, 2013.
PubMed
11) Phelan D, et al : Application of parameter display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr 27 : 888-895, 2014.
PubMed
12) Kumar S, et al : Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 : 989-995, 2012.
PubMed
13) Muchtar E, et al : Immunoglobulin Light-Chain Amyloidosis : From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematol 135 : 172-190, 2016.
PubMed
14) Maurer MS, et al : Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018.
PubMed
P.321 掲載の参考文献
1) Xia G, et al : Human iPSC Models to Study Orphan Diseases : Muscular Dystrophies. Curr Stem Cell Rep 4 : 299-309, 2018.
PubMed
2) Feingold B, et al : Management of Cardiac Involvement Associated With Neuromuscular Diseases : A Scientific Statement From the American Heart Association. Circulation 136 : e200-e231, 2017.
PubMed
3) Muntoni F, et al : Dystrophin and mutations : one gene, several proteins, multiple phenotypes. Lancet Neurol 2 : 731-740, 2003.
PubMed
4) Ogata H, et al : Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy. Int J Cardiol 115 : 190-195, 2007.
PubMed
5) Ishizaki M, et al : Female dystrophinopathy : Review of current literature. Neuromuscul Disord 28 : 572-581, 2018.
PubMed
6) Ferlini A, et al : X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 9 : 339-346, 1999.
PubMed
7) Shimizu M, et al : Gene mutations in adult Japanese patients with dilated cardiomyopathy. Circ J 69 : 150-153, 2005.
PubMed
8) Bione S, et al : Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 8 : 323-327, 1994.
PubMed
9) Sakata K, et al : High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation 111 : 3352-3358, 2005.
PubMed
10) Bonne G, et al : Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 21 : 285-288, 1999.
PubMed
11) Fatkin D, et al : Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341 : 1715-1724, 1999.
PubMed
12) Kumar S, et al : Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. J Am Coll Cardiol 68 : 2299-2307, 2016.
PubMed
13) Nakajima K, et al : Clinical Manifestations and Long-Term Mortality in Lamin A/C Mutation Carriers From a Japanese Multicenter Registry. Circ J 82 : 2707-2714, 2018.
PubMed
14) Fujino N, et al : Phenotype and Prognosis of the Lamin A/C Gene (LMNA) Mutation Carriers in Japan. Circ J 82 : 2699-2700, 2018.
PubMed
P.325 掲載の参考文献
1) Sweeley CC, Klionsky B : Fabry's disease : classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238 : 3148-3150, 1963.
PubMed
2) Brady RO, et al : Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276 : 1163-1167, 1967.
PubMed
3) Bishop DF, et al : Human alpha-galactosidase A : nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 83 : 4859-4863, 1986.
PubMed
4) Tsuji S, et al : Signal sequence and DNA-mediated expression of human lysosomal alpha-galactosidase A. Eur J Biochem 165 : 275-280, 1987.
PubMed
5) Nakao S, et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995.
PubMed
6) Spada M, et al : High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79 : 31-40, 2006.
PubMed
7) Lin HY, et al : High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2 : 450-456, 2009.
PubMed
8) Hwu WL, et al : Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G > A (IVS4+919G > A). Hum Mutat 30 : 1397-1405, 2009.
PubMed
9) Inoue T, et al : Newborn screening for Fabry disease in Japan : prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58 : 548-552, 2013.
 
10) Kawano M, et al : Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease. Am J Cardiol 99 : 261-263, 2007.
PubMed
11) Morimoto S, et al : Relief of left ventricular outflow obstruction by cibenzoline in a patient with Fabry's disease : a case report. Angiology 57 : 241-245, 2006.
 
12) Weidemann F, et al : Long-term effects of enzyme replacement therapy on fabry cardiomyopathy : evidence for a better outcome with early treatment. Circulation 119 : 524-529, 2009.
PubMed
P.331 掲載の参考文献
1) Kannel WB, McGee DL : Diabetes and cardiovascular disease. The Framingham study. JAMA 241 : 2035-2038, 1979.
PubMed
2) Kannel WB, McGee DL : Diabetes and glucose tolerance as risk factors for cardiovascular disease : the Framingham study. Diabetes Care 2 : 120-126, 1979.
PubMed
3) Yancy CW, et al : Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 : 1358-1365, 2001.
PubMed
4) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
5) Authors/Task Force Members, et al : ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD : the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 : 3035-3087, 2013.
 
6) Bando YK, Murohara T : Diabetes-related heart failure. Circ J 78 : 576-583, 2014.
PubMed
7) Yoldas T, et al : Subclinical left ventricular systolic and diastolic dysfunction in type 1 diabetic children and adolescents with good metabolic control. Echocardiography 35 : 227-233, 2018.
PubMed
8) Rijzewijk LJ, et al : Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52 : 1793-1799, 2008.
PubMed
9) Jia G, et al : Diabetic Cardiomyopathy : An Update of Mechanisms Contributing to This Clinical Entity. Circ Res 122 : 624-638, 2018.
PubMed
P.338 掲載の参考文献
1) Ewer MS, Ewer SM : Cardiotoxicity of anticancer treatments : what the cardiologist needs to know. Nat Rev Cardiol 7 : 564-575, 2010.
PubMed
2) Zamorano JL, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
3) Zhang S, et al : Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18 : 1639-1642, 2012.
PubMed
4) Ichikawa Y, et al : Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accurnulation. J Clin Invest 124 : 617-630, 2014.
PubMed
5) Speyer JL, et al : Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319 : 745-752, 1988.
PubMed
6) Curigliano G, et al : Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy : ESMO Clinical Practice Guidelines. Ann Oncol 23 (Suppl 7) : vii155-166, 2012.
 
7) Armenian SH, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
8) Shan K, et al : Anthracycline-induced cardiotoxicity. Ann Intern Med 125 : 47-58, 1996.
PubMed
9) Cardinale D, et al : Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 : 1981-1988, 2015.
PubMed
10) Ohtani K, et al : Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol, 2018 Oct 26. (doi : 10.1007/s00392-018-1386-0)
 
11) Hensley ML, et al : American Society of Clinical Oncology 2008 clinical practice guideline update : use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 : 127-145, 2009.
 
12) Onitilo AA, et al : Cardiovascular toxicity associated with adjuvant trastuzumab therapy : prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5 : 154-166, 2014.
PubMed
13) Narayan HK, et al : Detailed Echocardiographic Phenotyping in Breast Cancer Patients : Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up. Circulation 135 : 1397-1412, 2017.
PubMed
14) de Azambuja E, et al : Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 32 : 2159-2165, 2014.
PubMed
15) Chen J, et al : Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60 : 2504-2512, 2012.
 
P.344 掲載の参考文献
1) Sliwa K, et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12 : 767-778, 2010.
 
2) Demakis JG, Rahimtoola SH : Peripartum cardiomyopathy. Circulation 44 : 964-968, 1971.
PubMed
3) Kamiya CA, et al : Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy-. Circ J 75 : 1975-1981, 2011.
PubMed
4) Elkayam U : Clinical characteristics of peripartum cardiomyopathy in the United States : diagnosis, prognosis, and management. J Am Coll Cardiol 58 : 659-670, 2011.
PubMed
5) Bello N, et al : The relationship between pre-eclampsia and peripartum cardiomyopathy : a systematic review and meta-analysis. J Am Coll Cardiol 62 : 1715-1723, 2013.
PubMed
6) Hilfiker-Kleiner D, et al : A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 : 589-600, 2007.
PubMed
7) Haghikia A, et al : Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 108 : 366, 2013.
 
8) Patten IS, et al : Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485 : 333-338, 2012.
PubMed
9) Tannetta D, et al : Update of syncytiotrophoblast derived extracellular vesicles in normal pregnancy and preeclampsia. J Reprod Immunol 119 : 98-106, 2017.
PubMed
10) Ho L, et al : ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science 357 : 707-713, 2017.
PubMed
11) Ware JS, et al : Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med 374 : 233-241, 2016.
PubMed
12) Halkein J, et al : MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123 : 2143-2154, 2013.
PubMed
13) Sliwa K, et al : Evaluation of brolnocriptine in the treatment of acute severe peripartum cardiomyopathy : a proof-of-concept pilot study. Circulation 121 : 1465-1473, 2010.
PubMed
14) Hilfiker-Kleiner D, et al : Bromocriptine for the treatment of peripartum cardiomyopathy : a multicentre randomized study. Eur Heart J 38 : 2671-2679, 2017.
PubMed
15) McNamara DM, et al : Clinical Outcomes for Peripartum Cardiomyopathy in North America : Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66 : 905-914, 2015.
PubMed
P.351 掲載の参考文献
1) Takeda A : Mitochondrial cardiomyopathy. Pediatric Cardiology and Cardiac Surgery 33 : 287-296, 2017.
 
2) Holmgren D, et al : Cardiomyopathy in children with mitochondrial disease ; clinical course and cardiological findings. Eur Heart J 24 : 280-288, 2003.
PubMed
3) Meyers DE, et al : Mitochondrial cardiomyopathy : pathophysiology, diagnosis, and management. Tex Heart 40 : 385-394, 2013.
PubMed
4) El-Hattab AW, Scaglia F : Mitochondrial Cardiomyopathies. Front Cardiovasc Med 3 : 25, 2016.
PubMed
5) Finsterer J : Histiocytoid cardiomyopathy : a mitochondrial disorder. Clin Cardiol 31 : 225-227, 2008.
PubMed
6) Khambatta S, et al : Kearns-Sayre syndrome : acase series of 35 adults and children. Int J Gen Med 7 : 325-332, 2014.
 
7) Goto Y, et al : A mutation in the tRNA (Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348 : 651-653, 1990.
PubMed
8) Anan R, et al : Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 91 : 955-961, 1995.
 
9) Takeda A, et al : Eponym : Barth syndrome. Eur J Pediatr 170 : 1365-1367, 2011.
PubMed
10) Bernier FP, et al : Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 59 : 1406-1411, 2002.
PubMed
11) 村山圭, ほか : ミトコンドリア心筋症の診断の進め方は? . ミトコンドリア病診療マニュアル 2017, p69-76, 診断と治療社, 2016.
 
12) Ghirlanda G, et al : Evidence of plasma CoQIO-lowering effect by HMG-CoA reductase inhibitors : a double-blind, placebo-controlled study. J Clin Pharmacol 33 : 226-229, 1993.
PubMed
13) Epstein AE, et al : 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 127 : e283-352, 2013.
 
14) Russo AM, et al : ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy : a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 61 : 1318-1368, 2013.
 
15) 重症心不全に対する植込型補助人工心臓治療ガイドライン. 日本循環器学会/日本心臓血管外科学会合同ガイドライン (2011-2012年度合同研究班報告), 2014.
 
P.357 掲載の参考文献
1) 鈴木隆浩, 小澤敬也 : 日本の現状と病態. 日本内科学会雑誌 99 : 1233-1240, 2010.
 
2) 鈴木隆浩 : 輸血後鉄過剰症の病態と治療. 北里医学 47 : 1-9, 2017.
Medical*Online
3) 小澤敬也 : 輸血後鉄過剰症の診療ガイド. 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究 (平成20年度), 2008.
 
4) Pereira NL, et al : Spectrum of Restrictive and Infiltrative Cardiomyopathies : Part 2 of a 2-Part Series. J Am Coll Cardiol 71 : 1149-1166, 2018.
 
5) 岩永善高 : 鉄過剰と心障害. 日本内科学会雑誌 99 : 1241-1247, 2010.
 
6) Kirk P, et al : Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120 : 1961-1968, 2009.
PubMed
7) Takatoku M, et al : Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78 : 487-494, 2007.
PubMed
8) Ikuta K, et al : Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol 105 : 353-360, 2017.
PubMed
9) Pennell DJ, et al : Sustained improvements in myocardial T2* over 2 years in severely ironoverloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol 90 : 91-96, 2015.
PubMed
10) Modell B, et al : Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10 : 42, 2008.
PubMed
11) Rose C, et al : Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34 : 864-870, 2010.
PubMed
12) Sadaf A, et al : Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev 7 : CD011626, 2018.
PubMed
13) Swedberg K, et al : Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 : 1210-1219, 2013.
PubMed
14) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
P.364 掲載の参考文献
1) Fernandez-Sola J : Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol 12 : 576-587, 2015.
PubMed
2) Fauchier L, et al : Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 21 : 306-314, 2000.
PubMed
3) Ware JS, et al : Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol 71 : 2293-2302, 2018.
PubMed
4) Guzzo-Merello G, et al : Alcoholic cardiomyopathy. World J Cardiol 6 : 771-781, 2014.
PubMed
5) Lazarevic AM, et al : Early changes in left ventricular function in chronic asymptomatic alcoholics : relation to the duration of heavy drinking. J Am Coll Cardiol 35 : 1599-1606, 2000.
 
6) Skotzko CE, et al : Alcohol use and congestive heart failure : incidence, importance, and approaches to improved history taking. Heart Fail Rev 14 : 51-55, 2009.
PubMed
7) Gongalves A, et al : Alcohol consumption and risk of heart failure : the Atherosclerosis Risk in Communities Study. Eur Heart J 36 : 939-945, 2015.
PubMed
8) Holmes MV, et al : Association between alcohol and cardiovascular disease : Mendelian randomisation analysis based on individual participant data. BMJ 349 : g4164, 2014.
PubMed
9) Knott CS, et al : All cause mortality and the case for age specific alcohol consumption guidelines : pooled analyses of up to 10 population based cohorts. BMJ 350 : h384, 2015.
PubMed
10) Krenz M, Korthuis RJ : Moderate ethanol ingestion and cardiovascular protection : from epidemiologic associations to cellular mechanisms. J Mol Cell Cardiol 52 : 93-104, 2012.
PubMed
11) Cheng CP, et al : Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation 114 : 226-236, 2006.
PubMed
12) Gavazzi A, et al : Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol 85 : 1114-1118, 2000.
PubMed
13) Rodrigues P, et al : Association Between Alcohol Intake and Cardiac Remodeling. J Am Coll Cardiol 72 : 1452-1462, 2018.
PubMed
14) 坂本央, 長谷部直幸 : アルコール性心筋障害. 最新医学別冊 新しい診断と治療のABC62/消化器9アルコール性肝障害, p175-182, 2009.
 
15) Iles L, et al : Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52 : 1574-1580, 2008.
PubMed
P.370 掲載の参考文献
1) Klein I, Danzi S : Thyroid Disease and the Heart. Curr Probl Cardiol 41 : 65-92, 2016.
PubMed
2) Osman F, et al : Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy : a matched case-control study. J Am Coll Cardiol 49 : 71-81, 2007.
PubMed
3) Siu CW, et al : Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 93 : 483-487, 2007.
PubMed
4) Vallabhajosula S, et al : Hyperthyroidism and pulmonary hypertension : an important association. Am J Med Sci 342 : 507-512, 2011.
PubMed
5) Nakazawa H, et al : Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 21 : 327-333, 2000.
 
6) Bartalena L, et al : 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J 7 : 55-66, 2018.
PubMed
7) Osuna PM, et al : Hyperthyroidism and the Heart. Methodist Debakey Cardiovasc J 13 : 60-63, 2017.
PubMed
8) Selmer C, et al : Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events : a large population study. J Clin Endocrinol Metab 99 : 2372-2382, 2014.
PubMed
9) Biondi B, et al : The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J 4 : 149-163, 2015.
PubMed
10) Kasagi K, et al : Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters. Thyroid 19 : 937-944, 2009,
 
11) Udovcic M, et al : Hypothyroidism and the Heart. Methodist Debakey Cardiovasc J 13 : 55-59, 2017.
PubMed
12) Rodondi N, et al : Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304 : 1365-1374, 2010.
PubMed
13) Pearce SH, et al : 2013 ETA Guideline : Management of Subclinical Hypothyroidism. Eur Thyroid J 2 : 215-228, 2013.
PubMed
P.375 掲載の参考文献
1) 阿部達夫, ほか : 脚気心および脚気ニューロパチーの成因に関する研究-最近の脚気について. 栄と食糧 30 : 323-328, 1977.
 
2) 栗山勝, 中川広一 : 高齢者のビタミンB1欠乏. ビタミン 80 : 1-5, 2006.
 
3) 遠藤裕 : ビタミンB1欠乏症. 救急医療ジャーナル 19 (3) : 28-32, 2011.
 
4) 春田英律, ほか : 胃癌患者における胃全摘・幽門側胃切除の周術期ビタミンB1投与に関する検討. 外科と代謝・栄養 44 (1) : 1-7, 2010.
Medical*Online
5) 藤田一郎 : スポーツドリンクの多飲と脚気. 医学のあゆみ 156 : 525, 1991.
Medical*Online
6) 日出山健, ほか : 呼吸苦にて救急受診した脚気衝心の1症例. 超音波検査技術 37 : 484, 2012.
Medical*Online
7) 清水悠, ほか : 衝心脚気と判明した治療抵抗性急性左心不全の1例. ICUとCCU 35 : 853, 2011.
Medical*Online
8) King JF, et al : Acute pernicious beriberi heart disease. Chest 61 : 512-514, 1972.
PubMed
9) Wakabayashi A, et al : A clinical study on thiamine deficiency. Jpn Circ J 43 : 995-999, 1979.
PubMed
10) 糸川嘉則 : ビタミン利用障害とビタミン依存症. CLINICIAN 395 : 932-937, 1990.
 
11) Donnino MW, et al : Myths and misconceptions of Wernicke's encephalopathy : what every emergency physician should know. Ann Emerg Med 50 : 715-721, 2007.
PubMed
12) 厚生労働省 : 日本人の食事摂取基準 (2015年版) の概要.
 
P.382 掲載の参考文献
1) Klein AL, et al : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease : endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Cornputed Tomography. J Am Soc Echocardiogr 26 : 965-1012. e15, 2013.
 
2) Appleton C, et al : Cardiac Tamponade. Cardiol Clin 35 : 525-537, 2017.
PubMed
3) Azarbal A, LeWinter MM : Pericardial Effusion. Cardiol Clin 35 : 515-524, 2017.
PubMed
4) Ben-Horin S, et al : Large symptomatic pericardial effusion as the presentation of unrecognized cancer : a study in 173 consecutive patients undergoing pericardiocentesis. Medicine (Baltimore) 85 : 49-53, 2006.
 
5) Orbach A, et al : Contemporary evaluation of the causes of cardiac tamponade : Acute and long-term outcomes. Cardiol J 23 : 57-63, 2016.
PubMed
6) Beck CS : Two cardiac compression triads. JAMA 104 : 714-716, 1935.
 
7) Sternbach G : Claude Beck : cardiac compression triads. J Emerg Med 6 : 417-419, 1988.
 
8) Reddy PS, et al : Cardiac tamponade : hemodynamic observations in man. Circulation 58 : 265-272, 1978.
PubMed
9) Steven McGee : 頸静脈の視診. マクギーの身体診断学 [原著第2版] (柴田寿彦訳), p258-270, 診断と治療社, 2009.
 
10) Curtiss EI, et al : Pulsus paradoxus : definition and relation to the severity of cardiac tamponade. Am Heart J 115 : 391-398, 1988.
 
11) Clark JA, et al : Comparison of traditional and plethysmographic methods for measuring pulsus paradoxus. Arch Pediatr Adolesc Med 158 : 48-51, 2004.
PubMed
12) Spodick DH : Low atrial natriuretic factor levels and absent pulmonary edema in pericardial compression of the heart. Am J Cardiol 63 : 1271-1272, 1989.
PubMed
13) Oh JK, et al : Pericardial diseases. In : The Echo Manual, 3rd ed, p289-309, Lippincott Williams and Wilkins, Philadelphia, 2006
 
14) Oh JK, et al : Transient constrictive pericarditis : diagnosis by two-dimensional Doppler echocardiography. Mayo Clin Proc 68 : 1158-1164, 1993.
PubMed
15) Tsang TS, et al : Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses : clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 77 : 429-436, 2002.
PubMed
16) El Haddad D, et al : Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. J Am Coll Cardiol 66 : 1119-1128, 2015.
PubMed
P.388 掲載の参考文献
1) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
2) Leya FS, et al : The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45 : 1900-1902, 2005.
PubMed
P.392 掲載の参考文献
1) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
2) Rehman KA, et al : Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease : Insights and pathophysiology. Clin Cardiol 40 : 839-846, 2017.
PubMed
3) Bataille S, et al : Pericarditis in uremic patients : serum albumin and size of pericardial effusion predict drainage necessity. J Nephrol 28 : 97-104, 2015.
PubMed
4) Sadjadi SA, Mashahdian A : Uremic pericarditis : a report of 30 cases and review of the literature. Am J Case Rep 16 : 169-173, 2015.
PubMed
5) Bentata Y, et al : Uremic pericarditis in patients with End Stage Renal Disease : Prevalence, symptoms and outcome in 2017. Am J Emerg Med 36 : 464-466, 2018.
PubMed
6) 越智章展, ほか : 血液透析導入後, 発熱と心膜摩擦音にて尿毒症性心膜炎を発症し軽快した1例. 大阪透析研究会会誌 29 : 55-58, 2011.
Medical*Online
7) 伊藤千春 : 心外膜炎, 心タンポナーデ. 腎と透析 68 : 860-863, 2010.
Medical*Online
8) Alpert MA, Ravenscraft MD : Pericardial involvement in end-stage renal disease. Am J Med Sci 325 : 228-236, 2003.
PubMed
9) De Pace NL, et al : Predicting success of intensive dialysis in the treatment of uremic pericarditis. Am J Med 76 : 38-46, 1984.
PubMed
P.397 掲載の参考文献
1) 大北裕, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf] (2019年2月閲覧)
 
2) Nishimura RA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-643, 2014.
 
3) Annabi MS, et al : Dobutamine Stress Echocardiography for Management of Low-Flow, Low-Gradient Aortic Stenosis. J Am Coll Cardiol 71 : 475-485, 2018.
PubMed
4) Hachicha Z, et al : Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation 115 : 2856-2864, 2007.
PubMed
5) Yamashita E, et al : Prognostic value of paradoxical low-gradient severe aortic stenosis in Japan : Japanese Multicenter Aortic Stenosis Study, Retrospective (JUST-R) Registry. J Cardiol 65 : 360-368, 2015.
 
6) Thaden JJ, et al : Doppler Imaging in Aortic Stenosis : The Importance of the Nonapical Imaging Windows to Determine Severity in a Contemporary Cohort. J Am Soc Echocardiogr 28 : 780-785, 2015.
 
7) Daubert MA, et al : Long-term valve performance of TAVR and SAVR : a report from the PARTNER I trial. JACC Cardiovasc Imaging, 2016. [Epub ahead of print]
 
8) Smith N, et al : Severe aortic stenosis with impaired left ventricuiar function and clinical heart failure : results of valve replacement. Circulation 58 : 255-264, 1978.
PubMed
9) Dahou A, et al : Impact of AVR on LV Remodeling and Function in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis With Preserved LVEF. JACC Cardiovasc Imaging 10 : 88-89, 2017.
PubMed
10) Perez Del Villar C, et al : The Functional Significance of Paradoxical Low-Gradient Aortic Valve Stenosis : Hemodynamic Findings During Cardiopulmonary Exercise Testing. JACC Cardiovasc Imaging 10 : 29-39, 2017.
PubMed
11) Lang RM, et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39. e14, 2015.
 
12) Chan KL, et al : Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis : results of the aortic stenosis progression observation : measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121 : 306-314, 2010.
PubMed
13) Rossebe AB, et al : Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 : 1343-1356, 2008.
 
14) Leon MB, et al : Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 : 1597-1607, 2010.
PubMed
15) Smith CR, et al : Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 : 2187-2198, 2011.
PubMed
16) Leon MB, et al : Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 374 : 1609-1620, 2016.
 
17) Thourani VH, et al : Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients : a propensity score analysis. Lancet 387 : 2218-2225, 2016.
PubMed
18) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 : e1159-e1195, 2017.
 
19) Yoshitani H, et al : Surgical as Opposed to Transcatheter Aortic Valve Replacement Improves Basal Interventricular Septal Hypertrophy. Circ J 82 : 2887-2895, 2018.
PubMed
P.404 掲載の参考文献
1) Nishimura RA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-643, 2014.
 
2) Dujardin KS, et al : Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 99 : 1851-1857, 1999.
PubMed
3) Chaliki HP, et al : Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 106 : 2687-2693, 2002.
PubMed
4) 土肥薫 : 大動脈弁閉鎖不全症における血行動態評価. 真っ向勝負の大動脈弁狭窄症・閉鎖不全症 (大西勝也編), p131-134, メディカ出版, 2016.
 
5) Lancellotti P, et al : European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1 : aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 11 : 223-244, 2010.
PubMed
6) Ewe SH, et al : Detection of subtle left ventricular systolic dysfunction in patients with significant aortic regurgitation and preserved left ventricular ejection fraction : speckle tracking echocardiographic analysis. Eur Heart J Cardiovasc Imaging 16 : 992-999, 2015.
PubMed
7) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
P.409 掲載の参考文献
1) Hugenholtz PG, et al : The spectrum of pure mitral stenosis. Hemodynamic studies in relation to clinical disability. Am J Cardiol 10 : 773-784, 1962.
PubMed
2) Reyes VP, et al : Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 331 : 961-967, 1994.
PubMed
3) Horstkotte D, et al : Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J 12 (Suppl B) : 55-60, 1991.
 
4) Ward C, Hancock BW : Extreme pulmonary hypertension caused by mitral valve disease. Natural history and results of surgery. Br Heart J 37 : 74-78, 1975.
PubMed
5) Pasca I, et al : Survival in Patients with Degenerative Mitral Stenosis : Results from a Large Retrospective Cohort Study. J Am Soc Echocardiogr 29 : 461-469, 2016.
PubMed
6) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
7) Hernandez R, et al : Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon. Circulation 99 : 1580-1586, 1999.
PubMed
8) Bouleti C, et al : Reinterventions after percutaneous mitral commissurotomy during long-term followup, up to 20 years : the role of repeat percutaneous mitral commissurotomy. Eur Heart J 34 : 1923-1930, 2013.
PubMed
9) Palacios IF, et al : Which patients benefit from percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and postvalvuloplasty variables that predict long-term outcome. Circulation 105 : 1465-1471, 2002.
PubMed
10) Whitlock RP, et al : Antithrombotic and thrombolytic therapy for valvular disease : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 : (2 Suppl) : e576s-e600s, 2012.
 
11) Boonyasirinant T, et al : Clinical and echocardiographic parameters and score for the left atrial thrombus formation prediction in the patients with mitral stenosis. J Med Assoc Thai 90 (Suppl 2) : 9-18, 2007.
 
12) Manjunath CN, et al : Incidence and predictors of left atrial thrombus in patients with rheumatic mitral stenosis and sinus rhythm : a transesophageal echocardiographic study. Echocardiography 28 : 457-460, 2011.
PubMed
13) Meister SG, et al : Propranolol in mitral stenosis during sinus rhythm. Am Heart J 94 : 685-688, 1977.
PubMed
14) Antonini-Canterin F, et al : Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation 121 : 2130-2136, 2010.
 
P.416 掲載の参考文献
1) Rossi A, et al : Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97 : 1675-1680, 2011.
PubMed
2) Kaneko H, et al : Prevalence and the long-term prognosis of functional mitral regurgitation in Japanese patients with symptomatic heart failure. Heart Vessels 29 : 801-807, 2014.
 
3) Kaneko H, et al : Functional mitral regurgitation and left ventricular systolic dysfunction in the recent era of cardiovascular clinical practice, an observational cohort study. Hypertens Res 37 : 1082-1087, 2014.
PubMed
4) Ling LH, et al : Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 335 : 1417-1423, 1996.
PubMed
5) Tribouilloy CM, et al : Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation : rationale for optimizing surgical indications. Circulation 99 : 400-405, 1999.
PubMed
6) Grigioni F, et al : Ischemic mitral regurgitation : long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103 : 1759-1764, 2001.
PubMed
7) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
 
8) Enriquez-Sarano M, et al : Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation 90 : 830-837, 1994.
PubMed
9) Ling LH, et al : Early surgery in patients with mitral regurgitation due to flail leaflets : a long-term outcome study. Circulation 96 : 1819-1825, 1997.
PubMed
10) Enriquez-Sarano M, et al : Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation 91 : 1022-1028, 1995.
PubMed
11) Agricola E, et al : Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail 11 : 581-587, 2009.
PubMed
12) Wu AH, et al : Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45 : 381-387, 2005.
PubMed
13) Mihaljevic T, et al : Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol 49 : 2191-2201, 2007.
PubMed
14) Smith PK, et al : Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 371 : 2178-2188, 2014.
PubMed
15) Michler RE, et al : Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. N Engl J Med 374 : 1932-1941, 2016.
PubMed
16) Acker MA, et al : Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 370 : 23-32, 2014.
PubMed
17) Feldman T, et al : Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364 : 1395-1406, 2011.
 
18) Stone GW, et al : Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
19) Kaneko H, et al : Impact of residual mitral regurgitation after MitraClip implantation. Int J Cardiol 227 : 813-819, 2017.
PubMed
20) Neuss M, et al : Elevated Mitral Valve Pressure Gradient After MitraClip Implantation Deteriorates Long-Term Outcome in Patients With Severe Mitral Regurgitation and Severe Heart Failure. JACC Cardiovasc Interv 10 : 931-939, 2017.
PubMed
21) Taramasso M, et al : Percutaneous mitral valve repair and replacement : complementary or competitive techniques? EuroIntervention 12 : Y97-Y101, 2016.
 
P.421 掲載の参考文献
1) Capodanno D, et al : Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves : a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38 : 3382-3390, 2017.
 
2) Senage T, et al : Early structural valve deterioration of Mitroflow aortic bioprosthesis : mode, incidence, and impact on outcome in a large cohort of patients. Circulation 130 : 2012-2020, 2014.
 
3) Banbury MK, et al : Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 72 : 753-757, 2001.
 
4) Dvir D, et al : Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation 137 : 388-399, 2018.
PubMed
5) Farivar RS, Cohn LH : Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 126 : 969-975, 2003.
PubMed
6) Le Tourneau T, et al : Cardiovascular risk factors as predictors of early and late survival after bioprosthetic valve replacement for aortic stenosis. J Heart Valve Dis 16 : 483-488, 2007.
PubMed
7) Arsalan M, Walther T : Durability of prostheses for transcatheter aortic valve implantation. Nat Rev Cardiol 13 : 360-367, 2016.
PubMed
8) Kataruka A, Otto CM : Valve durability after transcatheter aortic valve implantation. J Thorac Dis 10 : S3629-S3636, 2018.
PubMed
9) Zoghbi WA, et al : Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound : a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 22 : 975-1014 ; quiz 1082-1084, 2009.
 
10) Lancellotti P, et al : Recommendations for the imaging assessment of prosthetic heart valves : a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 17 : 589-590, 2016.
 
11) Chenot F, et al : Evaluation of anatomic valve opening and leaflet morphology in aortic valve bioprosthesis by using multidetector CT : comparison with transthoracic echocardiography. Radiology 255 : 377-385, 2010.
PubMed
12) Ribeiro HB, et al : Cardiovascular Magnetic Resonance to Evaluate Aortic Regurgitation After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 68 : 577-585, 2016.
PubMed
13) Falk V, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 52 : 616-664, 2017.
 
14) Deeb GM, et al : 1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. JACC Cardiovasc Interv 10 : 1034-1044, 2017.
PubMed
P.431 掲載の参考文献
1) 和泉徹ほか : 循環器病の診断と治療に関するガイドライン. 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版).
 
2) Caforio AL, et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2648a-2648d, 2013.
 
3) Kindermann I, et al : Update on myocarditis. J Am Coll Cardiol 59 : 779-792, 2012.
PubMed
4) Friedrich MG, et al : Cardiovascular magnetic resonance in myocarditis : AJACC White Paper. J Am Coll Cardiol 53 : 1475-1487, 2009.
 
5) Frustaci A, Chimenti C : Immunosuppressive therapy in myocarditis. Circ J 79 : 4-7, 2015.
PubMed
6) Bowles NE, et al : Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 42 : 466-472, 2003.
PubMed
7) Talmon Y, et al : Acute myopericarditis complicating acute tonsillitis : beware the young male patient with tonsillitis complaining of chest pain. Ann Otol Rhinol Laryngol 117 : 295-297, 2008.
 
8) Cooper LT, et al : Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336 : 1860-1866, 1997.
 
9) Okura Y, et al : A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41 : 322-329, 2003.
PubMed
10) Brambatti M, et al : Eosinophilic Myocarditis : Characteristics, Treatment, and Outcomes. J Am Coll Cardiol 70 : 2363-2375, 2017.
PubMed
11) Sabatine MS, et al : Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. N Engl J Med 357 : 2167-2178, 2007.
PubMed
12) Mason JW, et al : A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333 : 269-275, 1995.
 
13) McNamara DM, et al : Intervention in myocarditis and acute cardiomyopathy with immune globulin : Results from the randomized placebo controlled IMAC trial. Circulation 100 (Suppl 1) : i-22, 1999.
 
14) Bhatt GC, et al : Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis. Pediatr Cardiol 33 : 1370-1376, 2012.
PubMed
15) Kandolin R, et al : Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 6 : 15-22, 2013.
PubMed
16) Kindermann I, et al : Predictors of outcome in patients with suspected myocarditis. Circulation 118 : 639-648, 2008.
PubMed
P.437 掲載の参考文献
1) Fiedler A : Ueber acute interstitielle Myokarditis. In : Festschrift zur Feier des funzigjahrigen Bestehens der Dresdner Liedertafel 1889, p3, Dresden-Friedrichstadt, Naumann, Dresden, 1889.
 
2) McCarthy RE, et al : Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 : 690-695, 2000.
PubMed
3) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) : 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf]
 
4) Hiramitsu S, et al : Significance of transient left ventricular wall thickening in acute lymphocytic myocarditis. Heart Vessels 22 : 25-29, 2007.
PubMed
5) Naruke T, et al : End-tidal carbon dioxide concentration can estimate the appropriate timing for weaning off from extracorporeal membrane oxygenation for refractory circulatory failure. Int Heart J 51 : 116-120, 2010.
PubMed
6) Mason JW, et al : A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333 : 269-275, 1995.
 
7) Cooper LT, et al : Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336 : 1860-1866, 1997.
 
8) Kato S, et al : Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 22 : 48-51, 2007.
PubMed
9) Johnson DB, et al : Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375 : 1749-1755, 2016.
PubMed
10) Reuben A, et al : Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6 : e1361097, 2017.
PubMed
11) Tajiri K, et al : Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol 48 : 7-12, 2018.
PubMed
12) Semper H, et al : Drug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lung. Lung Cancer 99 : 117-119, 2016.
 
13) Brustle K, Heidecker B : Checkpoint inhibitor induced cardiotoxicity : managing the drawbacks of our newest agents against cancer. Oncotarget 8 : 106165-106166, 2017.
PubMed
14) Tajmir-Riahi A, et al : Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. J Immunother 41 : 35-38, 2018.
 
P.449 掲載の参考文献
1) Shiina Y, et al : Prevalence of adult patients with congenital heart disease in Japan. Int J Cardiol 146 : 13-16, 2011.
PubMed
2) Brickner ME, et al : Congenital heart disease in adults. First of two parts. N Engl J Med 342 : 256-263, 2000.
PubMed
3) Baumgartner H, et al : ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 31 : 2915-2957, 2010.
PubMed
4) Gatzoulis MA, et al : Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 340 : 839-846, 1999.
PubMed
5) Kijima Y, et al : Treat and Repair Strategy in Patients With Atrial Septal Defect and Significant Pulmonary Arterial Hypertension. Circ J 80 : 227-234, 2016.
PubMed
6) Beghetti M, Galie N : Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 53 : 733-740, 2009.
 
7) Galie N, et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 : 67-119, 2016.
 
8) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
9) Gatzoulis MA, et al : Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot : a multicentre study. Lancet 356 : 975-981, 2000.
PubMed
10) Bokma JP, et al : Effect of Losartan on Right Ventricular Dysfunction : Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot : Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot. Circulation 137 : 1463-1471, 2018.
PubMed
11) van der Bom T, et al : Effect of valsartan on systemic right ventricular function : adouble-blind, randomized, placebo-controlled pilot trial. Circulation 127 : 322-330, 2013.
 
12) Dennis M, et al : Clinical Outcomes in Adolescents and Adults After the Fontan Procedure. J Am Coll Cardiol 71 : 1009-1017, 2018.
PubMed
13) Ohuchi H, et al : Hemodynamic determinants of mortality after Fontan operation. Am Heart J 189 : 9-18, 2017.
PubMed
14) Kuwabara M, et al : Liver Cirrhosis and/or Hepatocellular Carcinoma Occurring Late After the Fontan Procedure-A Nationwide Survey in Japan. Circ J 82 : 1155-1160, 2018.
 
15) Hebert A, et al : Bosentan improves exercise capacity in adolescents and adults after Fontan operation : the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation 130 : 2021-2030, 2014.
PubMed
P.455 掲載の参考文献
1) Schillaci G, et al : A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. J Electrocardiol 45 : 617-623, 2012.
PubMed
2) Reichek N, Devereux RB : Left ventricular hypertrophy : relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 63 : 1391-1398, 1981.
PubMed
3) Drazner MH : The progression of hypertensive heart disease. Circulation 123 : 327-334, 2011.
PubMed
4) Levy D, et al : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 : 1561-1566, 1990.
PubMed
5) Stevens SM, et al : Increased left ventricular mass as a predictor of sudden cardiac death : is it time to put it to the test? Circ Arrhythm Electrophysiol 6 : 212-217, 2013.
 
6) Beache GM, et al : Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation 104 : 1214-1217, 2001.
PubMed
7) Norton GR, et al : Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 39 : 664-671, 2002.
PubMed
8) Adams KF, et al : Characteristics and outcomes of patients hospitalized for heart failure in the United States : rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 : 209-216, 2005.
 
9) Tsuchihashi-Makaya M, et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009.
PubMed
10) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
11) Mentz RJ, et al : Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111 : 582-587, 2013.
PubMed
12) Sato N, et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013.
PubMed
13) Krakoff LR : Comments on ALLHAT and doxazosin. Curr Control Trials Cardiovasc Med 2 : 254-256, 2001.
PubMed
14) Messerli FH, et al : The Transition From Hypertension to Heart Failure : Contemporary Update. JACC Heart Fail 5 : 543-551, 2017.
PubMed
15) Chen N, et al : Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev (8) : CD003654, 2010.
PubMed
16) Thomopoulos C, et al : Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure-meta-analyses of randomized trials. J Hypertens 34 : 373-384 ; discussion 384, 2016.
PubMed
17) Bangalore S, et al : Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 52 : 1062-1072, 2008.
PubMed
18) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014.
PubMed
P.462 掲載の参考文献
1) Ito S, et al : Strain vessel hypothesis : a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 32 : 115-121, 2009.
PubMed
2) 高血圧治療ガイドライン 2019 (日本高血圧学会高血圧治療ガイドライン作成委員会編), 特定非営利活動法人日本雨血圧学会, 2019.
 
3) Hirsch AT, et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric. and abdominal aortic) : a collaborative report from the American Association for Vascuiar Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute ; Society for Vascular Nursing ; TransAtlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-654, 2006.
 
4) Vasbinder GB, et al : Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension : a meta-analysis. Ann Intern Med 135 : 401-411, 2001.
PubMed
5) Williams GJ, et al : Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis : paired and unpaired analysis. AJR Am J Roentgenol 188 : 798-811, 2007.
PubMed
6) Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine : Standard method for ultrasound evaluation of renal arterial lesions. J Med Ultrason (2001) 43 : 145-162, 2016.
 
7) Bax L, et al : Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function : a randomized trial. Ann Intern Med 150 : 840-848, W150-151, 2009.
 
8) Cooper CJ ; CORAL Investigator, et al : Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 : 13-22, 2014.
PubMed
9) ASTRAL Investigators ; Wheatley K, et al : Revascularization versus medical therapy for renalartery stenosis. N Engl J Med 361 : 1953-1962, 2009.
PubMed
10) Jenks S, et al : Balloon angioplasty, with and without stenting, versus medical therapy for hypertensive patients with renal artery stenosis. Cochrane Database Syst Rev (12) : CD002944, 2014.
PubMed
11) Riaz IB, et al : Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol 114 : 1116-1123, 2014.
PubMed
P.467 掲載の参考文献
1) Sinclair AM, et al : Secondary hypertension in a blood pressure clinic. Arch Intern Med 147 : 1289-1293, 1987.
 
2) Munakata M, et al : Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension-a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 29 : 515-521, 2006.
PubMed
3) Campese VM, et al : Hypertension in renal parenchymal disease : why is it so resistant to treatment? Kidney Int 69 : 967-973, 2006.
PubMed
4) Johnson RJ, et al : Pathogenesis of essential hypertension : historical paradigms and modern insights. J Hypertens 26 : 381-391, 2008.
PubMed
5) エビデンスに基づくCKD診療ガイドライン 2018 (日本腎臓学会編), 東京医学社, 2018.
 
6) エビデンスに基づく多発性嚢胞腎 (PKD) 診療ガイドライン 2017 (丸山彰一監, 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎疾患に関する調査研究班編), 東京医学社, 2017.
 
7) Granata A, et al : Cardiorenal syndrome type 4 : From chronic kidney disease to cardiovascular impairment. Eur J Intern Med 30 : 1-6, 2016.
PubMed
8) Ronco C : The Cardiorenal Syndrome : Basis and Common Ground for a Multidisciplinary Patient-Oriented Therapy. Cardiorenal Med 1 : 3-4, 2011.
PubMed
P.474 掲載の参考文献
1) Rossi GP, et al : A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48 : 2293-2300, 2006.
PubMed
2) Volpe C, et al : Screening for primary aldosteronism in a primary care unit. J Renin Angiotensin Aldosterone Syst 14 : 212-219, 2013.
 
3) Fardella CE, et al : Primary hyperaldosteronism in essential hypertensives : prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 : 1863-1867, 2000.
PubMed
4) Born-Frontsberg E, et al : Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism : results of the German Conn's Registry. J Clin Endocrinol Metab 94 : 1125-1130, 2009.
 
5) Conn JW, et al : Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107 : 159-172, 1964.
PubMed
6) Laragh JH, et al : Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 52 : 633-652, 1972.
PubMed
7) Nishimura M, et al : Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33 : 261-266, 1999.
PubMed
8) Milliez P, et al : Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 : 1243-1248, 2005.
PubMed
9) Mulatero P, et al : Long-term cardio-and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 98 : 4826-4833, 2013.
PubMed
10) Rossi GP, et al : Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62 : 62-69, 2013.
PubMed
11) Bernini G, et al : Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocrinol Invest 35 : 274-280, 2012.
PubMed
12) De Mello WC : Local Renin Angiotensin Aldosterone Systems and Cardiovascular Diseases. Med Clin North Am 101 : 117-127, 2017.
PubMed
13) Re RN : Mechanisms of disease : local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 1 : 42-47, 2004.
PubMed
14) SOLVD Investigators, et al : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
PubMed
15) McMurray JJ, et al : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial : Lancet 362 : 767-771, 2003.
PubMed
16) Pfeffer MA, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
17) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
18) Pierdomenico SD, Cuccurollo F : Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension : a meta-analysis. Am J Hypertens 23 : 876-881, 2010.
 
19) Gerdts E, et al : Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr 9 : 809-815, 2008.
PubMed
20) Zile MR, et al : Prevalence and significance of alterations in cardiac s tructure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 : 2491-2501, 2011.
 
21) Catena C, et al : Aldosterone and Left Ventricular Remodeling. Horm Metab Res 47 : 981-986, 2015.
PubMed
22) Yang Y, et al : Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. Hypertens Res 40 : 243-250, 2017.
PubMed
23) Paulus WJ, et al : How to diagnose diastolic heart failure : a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 : 2539-2550, 2007.
 
24) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
25) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
26) Zannad F, et al : Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 : 11-21, 2011.
PubMed
27) Ferrari R, et al : Heart failure with preserved ejection fraction : uncertainties and dilemmas. Eur J Heart Fail 17 : 665-671, 2015.
PubMed
28) Yusuf S, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 : 777-781, 2003.
PubMed
29) Massie BM, et al : Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 : 2456-2467, 2008.
PubMed
30) Mottram PM, et al : Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 : 558-565, 2004.
PubMed
31) Mak GJ, et al : Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54 : 1674-1682, 2009.
PubMed
32) Edelmann F, et al : Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction : the Aldo-DHF randomized controlled trial. JAMA 309 : 781-791, 2013.
PubMed
33) Pitt B, et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014.
PubMed
34) Brilla CG, Weber KT : Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120 : 893-901, 1992.
PubMed
35) Rocha R, et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-1810, 2002.
PubMed
36) Benitah Jp, Vassort G : Aldosterone upregulates Ca (2+) current in adult rat cardiomyocytes. Circ Res 85 : 1139-1145, 1999.
PubMed
37) Lalevee N, et al : Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 67 : 216-224, 2005.
PubMed
38) Wei J, et al : The effect of aldosterone antagonists for ventricular arrhythmia : a meta-analysis. Clin Cardiol 33 : 572-577, 2010.
PubMed
39) Swedberg K, et al : Eplerenone and atrial fibrillation in mild systolic heart failure : results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survlval Study in Heart Failure) study. J Am Coll Cardiol 59 : 1598-1603, 2012.
PubMed
40) Jaffe IZ, Mendelsohn ME : Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96 : 643-650, 2005.
PubMed
41) Nguyen Dinh Cat A, et al : The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 24 : 2454-2463, 2010.
PubMed
42) Benard L, et al : Effects of aldosterone on coronary function. Pharmacol Rep 61 : 58-66, 2009.
PubMed
43) Favre J, et al : Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 300 : H2035-2043, 2011.
PubMed
44) Catena C, et al : Aldosterone and the heart : from basic research to clinical evidence. Horm Metab Res 44 : 181-187, 2012.
PubMed
45) Cooper SA, et al : Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 : H2009-2023, 2007.
PubMed
46) Goodfriend TL, et al : Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 7 : 355-362, 1999.
PubMed
P.483 掲載の参考文献
1) 日本内分泌学会 (編) : 褐色細胞腫・パラガングリオーマ診療ガイドライン 2018. 日本内分泌学会雑誌 94 (Suppl) : 1-90, 2018.
 
2) 成瀬光栄, ほか (編) : 褐色細胞腫診療マニュアル 改訂第3版, p1-145, 診断と治療社, 2017.
 
3) Bernini G, et al : Carotid vascular remodeling in patients with pheochromocytoma. J Clin Endocrinol Metab 91 : 1754-1760, 2006.
PubMed
4) 田辺晶代, ほか : 褐色細胞腫における心血管系臓器障害 : 61例の解析. 日本内分泌学会雑誌 82 (Suppl) : 53-56, 2006.
 
5) Prejbisz A, et al : Cardiovascular manifestations of phaeochromocytoma. J Hypertens 29 : 2049-2060, 2011.
PubMed
6) Batisse-Lignier M, et al : Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies : Different Prognoses? : A Systematic Analytical Review. Medicine (Baltimore) 94 : e2198, 2015.
PubMed
7) Akashi YJ, et al : Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol 12 : 387-397, 2015.
PubMed
8) Yu R, et al : Cardiac complications as initial manifestation of pheochromocytoma : frequency, outcome, and predictors. Endocr Pract 18 : 483-492, 2012.
PubMed
9) Liaudet L, et al : Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. Heart Fail Rev 19 : 815-824, 2014.
 
10) 西井基継, 和泉徹 : カテコラミン心筋症・心筋炎. Heart View 8 : 74-78, 2004.
 
11) Giavarini A, et al : Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart 99 : 1438-1444, 2013.
PubMed
12) 清水優樹ほか : 副腎腫瘍精査入院中, 心原性ショックで発症したカテコラミン心筋症の1例. 心臓 40 : 863-869, 2008.
Medical*Online
13) Scholten A, et al : Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab 98 : 581-591, 2013.
 
14) Agarwal G, et al : Cardiovascular dysfunction and catecholamine cardiomyopathy in pheochromocytoma patients and their reversal following surgical cure : results of a prospective case-control study. Surgery 150 : 1202-1211, 2011.
PubMed
15) Ueda T, et al : Pheochromocytoma presenting as recurrent hypotension and syncope. Intern Med 44 : 222-227, 2005.
PubMed
16) 田地慶太郎, ほか : 塩酸コルホルシンダロパートとミルリノンを用いて管理した高度の心機能低下を来した褐色細胞腫の1症例. 麻酔 67 : 532-535, 2018.
Medical*Online
17) Yamaguchi S, et al : Gastrointestinal pseudo-obstruction after debulking surgery of malignant pheochromocytoma, improved by intravenous administration of alpha-adrenergic receptor blocker, phentolamine. Hypertens Res 33 : 753-754, 2010.
PubMed

XXII その他病態・年齢層の心不全の臨床的事項

P.495 掲載の参考文献
1) Abraham MR : Congenital Diseases of the Heart : Clinical-Physiological Considerations, 3rd ed, Wiley-Blackwell, Chichester, 2009.
 
2) 三浦真澄 : NICUにおける循環管理の基本的な知識. ネオネイタルケア 30 : 1116-1122, 2017.
Medical*Online
3) Huhta JC : Right ventricular function in the human fetus. J Perinat Med 29 : 381-389, 2001.
PubMed
4) Ojala TH, Hornberger LK : Fetal heart failure. Front Biosci (Schol Ed) 2 : 891-906, 2010.
PubMed
5) Machin GA : Hydrops revisited : literature review of 1,414 cases published in the 1980s. Am J Med Genet 34 : 366-390, 1989.
PubMed
6) Schmidt MR, et al : Maternal hyperglycemia improves fetal cardiac function during tachycardiaind uced heart failure in pigs. Circulation 110 : 2627-2630, 2004.
 
7) Huhta JC : Guidelines for the evaluation of heart failure in the fetus with or without hydrops. Pediatr Cardiol 25 : 274-286, 2004.
PubMed
8) Hofstaetter C, et al : A cardiovascular profile score in the surveillance of fetal hydrops. J Matern Fetal Neonatal Med 19 : 407-413, 2006.
 
9) Li Y, et al : Prediction of fetal outcome without intrauterine intervention using a cardiovascular profile score : a systematic review and meta-analysis. J Matern Fetal Neonatal Med 28 : 1965-1972, 2015.
 
10) 市塚清健, ほか : 胎児心機能の評価. 周産期医学 41 : 49-53, 2011.
Medical*Online
11) Mahle WT, et al : Echocardiographic evaluation of the fetus with congenital cystic adenomatoid malformation. Ultrasound Obstet Gynecol 16 : 620-624, 2000.
PubMed
12) 石井徹子 : 胎児心機能の評価. 日本小児循環器学会雑誌 32 : 379-386, 2016.
Medical*Online
13) Davey B, et al : Diagnosis and management of heart failure in the fetus. Minerva Pediatr 64 : 471-492, 2012.
PubMed
14) Jaeggi ET, et al : Agenesis of the ductus venosus that is associated with extrahepatic umbilical vein drainage : prenatal features and clinical outcome. Am J Obstet Gynecol 187 : 1031-1037, 2002.
PubMed
15) Eidem BW, et al : Quantitative assessment of fetal ventricular function : establishing normal values of the myocardial performance index in the fetus. Echocardiography 18 : 9-13, 2001.
PubMed
16) 江川真希子, ほか : 胎児心不全の治療. 周産期医学 41 : 55-58, 2011.
Medical*Online
17) Tworetzky W, Marshall AC : Balloon valvuloplasty for congenital heart disease in the fetus. Clin Perinatol 30 : 541-550, 2003.
PubMed
P.501 掲載の参考文献
1) 中澤誠, ほか : 未熟児新生児心不全の病態と治療. Fetal & Neonatal Medicine 4 (1) : 8-16, 2012.
Medical*Online
2) 豊島勝昭 : FGR (IUGR) に関する最新情報 循環器疾患とFGR (IUGR). Fetal & Neonatal Medicine 2 (2) : 89-95, 2010.
Medical*Online
3) 宮地鑑 : 先天性心疾患における低侵襲外科治療の現況. 日本小児循環器学会雑誌 27 (6) : 257-261, 2011.
Medical*Online
4) 豊島勝昭 : Stress-Velocity関係を指標として循環管理した在胎23, 24週の超早産児の検討. 日本周産期・新生児医学会雑誌 41 (3) : 535-542, 2005.
Medical*Online
5) 先崎秀明 : 周産期救急疾患への対応 妊産婦・新生児死亡を防ぐために 新生児救急疾患 心不全への対応. 周産期医学 40 (6) : 907-912, 2010.
 
6) 白石真大, 村上智明 : 新生児の薬物療法-update各論 循環器用薬 抗心不全薬. 周産期医学 48 (2) : 169-172, 2018.
 
P.506 掲載の参考文献
1) 一般社団法人日本老年医学会 : 健康長寿達成を支える老年医学推進5か年計画. p1-28, 2018年6月14日. [https://wwwjpn-geriat-soc.or.jp/about/5year_plan.html]
 
2) Braunwald E : Heart failure. JACC Heart Fail 1 : 1-20, 2013.
PubMed
3) Yasuda S, et al : The Current Status of Cardiovascular Medicine in Japan-Analysis of a Large Number of Health Records From a Nationwide Claim-Based Database, JROAD-DPC. Circ J 80 : 2327-2335, 2016.
PubMed
4) Hamaguchi S, et al : Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. -Areport from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) -. Circ J 75 : 2403-2410, 2011.
 
5) Lakatta EG, Levy D : Arterial and cardiac aging : major shareholders in cardiovascular disease enterprises : Part II : the aging heart in health : links to heart disease. Circulation 107 : 346-354, 2003.
PubMed
6) Shih H, et al : The aging heart and post-infarction left ventricular remodeling. J Am Coll Cardiol 57 : 9-17, 2011.
PubMed
7) Redfield MM : Heart Failure with Preserved Ejection Fraction. N Engl J Med 375 : 1868-1877, 2016.
PubMed
8) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coli Cardiol 70 : 776-803, 2017.
 
9) Barnett K, et al : Epidemiology of multimorbidity and implications for health care, research, and medical education : a cross-sectional study. Lancet 380 : 37-43, 2012.
PubMed
10) Yasuda S, et al : Current Status of Cardiovascular Medicine in the Aging Society of Japan. Circulation 138 : 965-967, 2018.
PubMed
11) Forman DE, et al : Multimorbidity in Older Adults With Cardiovascular Disease. J Am Coll Cardiol 71 : 2149-2161, 2018.
PubMed
12) Gohbara M, et al : Low activities of daily living associated with increased cardiovascular disease mortality in Japan-analysis of health records from a nationwide claim-based database, JROADDPC, Circ Rep 1 : 20-28, 2019. (doi : 10.1253/circrep.CR-18-0009)
 
13) Rodriguez-Pascual C, et al : Comprehensive geriatric assessment and hospital mortality among older adults with decompensated heart failure. Am Heart J 164 : 756-762, 2012.
PubMed
14) 鳥羽研二 : 高齢者総合的機能評価ガイドライン. 日本老年医学会雑誌 42 : 177-180, 2005.
 
15) 日本心不全学会ガイドライン委員会 (編) : 高齢心不全患者の治療に関するステートメント, p1-55, 一般社団法人日本心不全学会, 2016.
 
P.512 掲載の参考文献
1) Karamermer Y, Roos-Hesselink JW : Pregnancy and adult congenital heart disease. Expert Rev Cardiovasc Ther 5 : 859-869, 2007
PubMed
2) McLean KC, et al : Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol 207 : 135. e1-6, 2012.
 
3) Estelles A, et al : Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 165 : 138-142, 1991.
PubMed
4) Gabbe SG, et al (ed) : Obstetrics : Normal and Problem Pregnancies. Churchill Livingstone, New York, 1996.
 
5) Therrien J, et al : CCS Consensus Conference 2001 update : recommendations for the management of adults with congenital heart disease. Part I. Can J Cardiol 17 : 940-959, 2001.
PubMed
6) Therrien J, et al : CCS Consensus Conference 2001 update : recommendations for the management of adults with congenital heart disease. Part II. Can J Cardiol 17 : 1029-1050, 2001.
 
7) Perloff JK, et al : Pregnancy and congenital heart disease : the mother and the fetus. In : Congenital Heart Disease in Adults 2nd ed, p144-164, WB Saunders, 1998.
 
8) Regitz-Zagrosek V, et al : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 39 : 3165-3241, 2018.
PubMed
9) Siu SC, et al : Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 104 : 515-521, 2001.
PubMed
10) Drenthen W, et al : Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 31 : 2124-2132, 2010.
PubMed
11) Findik S, et al : Acute pulmonary edema secondary to long-term use of oral ritodrine in a woman with atriplet pregnancy. Int J Gynaecol Obstet 96 : 208-211, 2007.
 
12) Tanaka H, et al : Non-invasive monitoring of the cardiac effects of continuous intravenous oxytocin infusion during cesarean delivery. Int J Gynaecol Obstet 139 : 251-252, 2017.
PubMed
P.516 掲載の参考文献
1) 循環器領域における性差医療に関するガイドライン. Circulation Journal 74 (Suppl II) : 1085-1178, 2010.
 
2) Bairey Merz CN, et al ; WISE investigators : Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE Study) : Part II : gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 47 (3 Suppl) : S21-29, 2006.
 
3) Tsutsui H, et al : Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 71 : 449-454, 2007.
PubMed
4) Ho KK, et al : Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 : 107-115, 1993.
PubMed
5) Tsuchihashi-Makaya M, et al : Sex differences with respect to clinical characteristics, treatment, and long-term outcomes in patients with heart failure. Int J Cardiol 150 : 338-339, 2011.
PubMed
6) Levy D, et al : The progression from hypertension to congestive heart failure. JAMA 275 : 1557-1562, 1996.
PubMed
7) Hubert HB, et al : Obesity as an independent risk factor for cardiovascular disease : a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67 : 968-977, 1983.
PubMed
8) Masoudi FA, et al : Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 41 : 217-223, 2003.
PubMed
9) Cleland JG, et al : The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1 : patient characteristics and diagnosis. Eur Heart J 24 : 442-463, 2003.
PubMed
10) Douglas PS, et al : Hypertrophic remodeling : gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 32 : 1118-1125, 1998.
PubMed
11) Lam CS, et al : Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction : the Irbesartan in Heart Failure with Preserved Ejection Fraction (1-PRESERVE) trial. Circ Heart Fail 5 : 571-578, 2012.
PubMed
12) Shekelle PG, et al : Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status : a meta-analysis of major clinical trials. J Am Coll Cardiol 41 : 1529-1538, 2003.
PubMed
13) Hudson M, et al : Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure-a population study. Eur J Heart Fail 9 : 602-609, 2007.
PubMed
14) Sakata Y, et al : Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. Circ J 78 : 428-435, 2014.
 
15) Steinberg BA, et al : Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction : prevalence, therapies, and outcomes. Circulation 126 : 65-75, 2012.
PubMed

XXIII 特論

P.536 掲載の参考文献
1) Anzai A, et al : Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation 125 : 1234-1245, 2012.
PubMed
2) King KR, et al : IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat Med 23 : 1481-1487, 2017.
PubMed
3) Felix SB, et al : Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39 : 646-652, 2002.
PubMed
4) Trimpert C, et al : Immunoadsorption in dilated cardiomyopathy : long-term reduction of cardiodepressant antibodies. Eur J Clin Invest 40 : 685-691, 2010.
PubMed
5) Chojkier M : Inhibition of albumin synthesis in chronic diseases : molecular mechanisms. J Clin Gastroenterol 39 : S143-146, 2005.
PubMed
6) Mann DL, et al : Targeted anticytokine therapy in patients with chronic heart failure : results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 : 1594-1602, 2004.
PubMed
7) Kjekshus J, et al : Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 : 2248-2261, 2007.
PubMed
8) Sobirin MA, et al : Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ Res 111 : 1037-1047, 2012.
PubMed
P.542 掲載の参考文献
1) Takii T, et al : Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 74 : 93-100, 2010.
PubMed
2) Nishida T, et al : Extracorporeal cardiac shock wave therapy markedly ameliorates ischemiainduced myocardial dysfunction in pigs in vivo. Circulation 110 : 3055-3061, 2004.
PubMed
3) Fukumoto Y, et al : Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 17 : 63-70, 2006.
PubMed
4) Kikuchi Y, et al : Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 74 : 589-591, 2010.
PubMed
5) Ito K, et al : Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. Tohoku J Exp Med 219 : 1-9, 2009.
PubMed
6) 伊藤健太, 下川宏明 : 体外衝撃波を用いた非侵襲性血管新生治療. 日内会誌 99 : 2846-2852, 2010.
 
7) Ito K, et al : Extracorporeal shock wave therapy for ischemic cardiovascular disorders. Am J Cardiovasc Drugs 11 : 295-302, 2011.
PubMed
8) Uwatoku T, et al : Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. Coron Artery Dis 18 : 397-404, 2007.
PubMed
9) Ito Y, et al : Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. Coron Artery Dis 21 : 304-311, 2010.
PubMed
10) Abe Y, et al : Extracorporeal low-energy shock-wave therapy exerts anti-inflammatory effects in a rat model of acute myocardial infarction. Circ J 78 : 2915-2925, 2014.
 
11) Serizawa F, et al : Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J 76 : 1486-1493, 2012.
PubMed
12) Hayashi D, et al : Low-energy extracorporeal shock wave therapy enhances skin wound healing in diabetic mice : a critical role of endothelial nitric oxide synthase : Wound Repair Regen 20 : 887-895, 2012.
PubMed
13) Yamaya S, et al : Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury. J Neurosurg 121 : 1514-1525, 2014.
PubMed
14) Serizawa F, et al : Extracorporeal shock wave therapy induces therapeutic lymphangiogenesis in a rat model of secondary lymphoedema. Eur J Vasc Endovasc Surg 42 : 254-260, 2011.
 
15) Saito S, et al : Extracorporeal Shock Wave Therapy for Digital Ulcers of Systemic Sclerosis : A Phase 2 Pilot Study. Tohoku J Exp Med 238 : 39-47, 2016.
PubMed
P.548 掲載の参考文献
1) Tei C : Waon therapy : soothing warmth therapy. J Cardiol 49 : 301-304, 2007.
PubMed
2) Tei C, et al : Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 91 : 2582-2590, 1995.
PubMed
3) Basford JR, et al : Safety, acceptance, and physiologic effects of sauna bathing in people with chronic heart failure : a pilot report. Arch Phys Med Rehabil 90 : 173-177, 2009.
PubMed
4) 鄭忠和, ほか : QOLの向上を重視した慢性心不全の治療 : 温熱性血管拡張療法による臨床的検討. 日内会誌 84 : 1475-1482, 1996.
 
5) Kihara T, et al : Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol 39 : 754-759, 2002.
PubMed
6) Imamura M, et al : Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. J Am Coll Cardiol 38 : 1083-1088, 2001.
PubMed
7) Ikeda Y, et al : Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J 69 : 722-729, 2005.
PubMed
8) Kihara T, et al : Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ J 68 : 1146-1151, 2004.
PubMed
9) Kuwahata S, et al : Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure. J Cardiol 57 : 100-106, 2011.
PubMed
10) Fujita S, et al : Effect of Waon therapy on oxidative stress in chronic heart failure. Circ J 75 : 348-356, 2011.
 
11) Miyauchi T, et al : Waon therapy upregulates Hsp90 and leads to angiogenesis through the Aktendothelial nitric oxide synthase pathway in mouse hindlimb ischemia. Circ J 76 : 1712-1721, 2012.
PubMed
12) 鄭忠和 : 和温療法 : 全人的医療. 呼吸と循環 61 : 774-781, 2013.
 
13) Miyata M, et al : Beneficial effects of Waon therapy on patients with chronic heart failure : results of a prospective multicenter study. J Cardiol 52 : 79-85, 2008.
 
14) Kihara T, et al : Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol 53 : 214-218, 2009.
PubMed
15) Ikeda Y, et al : Effect of repeated sauna therapy on survival in TO-2 cardiomyopathic hamsters with heart failure. Am J Cardiol 90 : 343-345, 2002.
 
16) Tei C, et al : Waon Therapy for Managing Chronic Heart Failure-Results From a Multicenter Prospective Randomized WAON-CHF Study. Circ J 80 : 827-834, 2016.
PubMed
17) Ichiki T, et al : Neurohumoral Modulation During Waon Therapy in Chronic Heart Failure-Subanalysis of Waon-CHF Study. Circ J 81 : 709-716, 2017.
PubMed
18) Conceicao R, et al : Effect of Waon Therapy in Individuals with Heart Failure : A Systematic Review. J Cardiac Fail 24 : 204-206, 2018.
 
19) Kallstrom M, et al : Effects of sauna bath on heart failure : A systematic review and meta-analysls. Clin Cardiol 41 : 1491-1501, 2018.
PubMed
P.555 掲載の参考文献
1) Famm K, et al : Drug discovery : a jump-start for electroceuticals. Nature 496 : 159-161, 2013.
PubMed
2) Ardell JL, et al : Translational neurocardiology : preclinical models and cardioneural integrative aspects. J Physiol (Lond) 594 : 3877-3909, 2016.
PubMed
3) Li M, et al : Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109 : 120-124, 2004.
PubMed
4) Sabbah HN, et al : Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 16 : 171-178, 2011.
PubMed
5) Zhang Y, et al : Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2 : 692-699, 2009.
 
6) Bonaz B, et al : Vagus nerve stimulation : from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol Motil 25 : 208-221, 2013.
 
7) Hanna P, et al : Calming the Nervous Heart : Autonomic Therapies in Heart Failure. Card Fail Rev 4 : 92-98, 2018.
PubMed
8) Nishizaki A, et al : Optimal Titration Is Important to Maximize the Beneficial Effects of Vagal Nerve Stimulation in Chronic Heart Failure. J Card Fail 22 : 631-638, 2016.
PubMed
9) Pfeffer MA, Braunwald E : Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 : 1161-1172, 1990.
PubMed
10) Calvillo L, et al : Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 58 : 500-507, 2011.
PubMed
11) Schauerte P, et al : Ventricular rate control during atrial fibrillation by cardiac parasympathetic nerve stimulation : a transvenous approach. J Am Coll Cardiol 34 : 2043-2050, 1999.
PubMed
12) Arimura T, et al : Intravenous electrical vagal nerve stimulation prior to coronary reperfusion in a canine ischemia-reperfusion model markedly reduces infarct size and prevents subsequent heart failure. Int J Cardiol 227 : 704-710, 2017.
 
13) Vanoli E, et al : Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 68 : 1471-1481, 1991.
PubMed
14) Zhang Y, et al : Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility : therapeutic intensities do not increase arrhythmogenesis. Heart Rhythm 6 : 244-250, 2009.
 
15) Yoshida K, et al : Electrical Vagal Nerve Stimulation Ameliorates Pulmonary Vascular Remodeling and Improves Survival in Rats With Severe Pulmonary Arterial Hypertension. JACC Basic Transl Sci 3 : 657-671, 2018.
PubMed
P.560 掲載の参考文献
1) Jhund PS, et al : Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003 : a population study of 5.1 million people. Circulation 119 : 515-523, 2009.
PubMed
2) Tsuchihashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-a study in Fukuoka, Japan. Jpn Circ J 64 : 953-959, 2000.
PubMed
3) McAlister FA, et al : Multidisciplinary strategies for the management of heart failure patients at high risk for admission : a systematic review of randomized trials. J Am Coll Cardiol 44 : 810-819, 2004.
PubMed
4) Tsuchihashi-Makaya M, et al : Home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J 77 : 926-933, 2013.
PubMed
5) Dracup K, et al : Randomized, controlled trial to improve self-care in patients with heart failure living in rural areas. Circulation 130 : 256-264, 2014.
PubMed
6) Dendale P, et al : Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure : the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study. Eur J Heart Fail 14 : 333-340, 2012.
PubMed
7) Koehler F, et al : Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure : the telemedical interventional monitoring in heart failure study. Circulation 123 : 1873-1880, 2011.
 
8) Chaudhry SI, et al : Telemonitoring in patients with heart failure. N Engl J Med 363 : 2301-2309, 2010.
PubMed
9) Koehler F, et al : Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2) : a randomised, controlled, parallel-group, unmasked trial. Lancet 392 : 1047-1057, 2018.
PubMed
P.566 掲載の参考文献
1) 日本胸部外科学会J-MACS委員会 : 日本における補助人工心臓に関連した市販後のデータ収集, 2017. [http://www.jpats.org/uploads/uploads/files/J-MACS%20Statistical%20Report%EF%BC%882010%E5%B9%B46%E6%9C%88-2017%E5%B9%B47%E6%9C%88%EF%BC%89.pdf] (2019年2月閲覧)
 
2) 日本循環器学会/日本心臓血管外科学会合同ガイドライン (2011-2012年度合同研究班報告) 重症心不全に対する植込型補助人工心臓治療ガイドライン. [http://www.j-circ.or.jp/guideline/pdf/JCS2013_kyo_h.pdf] (2019年2月閲覧)
 
3) Dracup K, et al : Randomized, controlled trial to improve self-care in patients with heart failure living in rural areas. Circulation 130 : 256-264, 2014.
PubMed
4) 横田卓 : 慢性心不全に対するICTを活用したセルフケアサポートシステムの現状と今後. 心臓 49 : 93-97, 2017.
Medical*Online
5) Koehler F, et al : Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure : the telemedical interventional monitoring in heart failure study. Circulation 123 : 1873-1880, 2011.
 
6) Koehler E et al : Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2) : a randomised, controlled, parallel-group, unmasked trial. Lancet 392 : 1047-1057, 2018.
 
7) 厚生労働省 : オンライン診療の適切な実施に関する指針, 2018. [https://www.mhlw.go.jp/file/05-Shingikai-10801000-Iseikyoku-Soumuka/0000201789.pdf] (2019年3月閲覧)
 
8) Abraham WT, et al : Wireless pulmonary artery haemodynamic monitoring in chronic heart failure : a randomised controlled trial. Lancet 377 : 658-666, 2011.
PubMed
P.572 掲載の参考文献
1) Aoki T, et al : The Great East Japan Earthquake Disaster and cardiovascular diseases. Eur Heart J 33 : 2796-2803, 2012.
PubMed
2) Aoki T, et al : Effect of the Great East Japan Earthquake on cardiovascular diseases--report from the 10 hospitals in the disaster area. Circ J 77 : 490-493, 2013.
PubMed
3) Nishizawa M, et al : Aftershock Triggers Augmented Pressor Effects in Survivors : Follow-Up of the Great East Japan Earthquake. Am J Hypertens 28 : 1405-1408, 2015.
PubMed
4) Jiang W, et al : Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation 110 : 3452-3456, 2004.
PubMed
5) Kario K, et al : Development of a disaster cardiovascular prevention network. Lancet 378 : 1125-1127, 2011.
PubMed
6) Kario K : Measuring the effects of stress on the cardiovascular system during a disaster : the effective use of self-measured blood pressure monitoring. J Hypertens 28 : 657-659, 2010.
PubMed
7) Kario K, et al : Management of cardiovascular risk in disaster : Jichi Medical School (JMS) Proposal 2004. JMAJ 48 : 363-376, 2005.
 
8) Kario K et al : Factors associated with the occurrence and magnitude of earthquake-induced increases in blood pressure. Am J Med 111 : 379-384, 2001.
PubMed
9) Kario K, et al : "White coat" hypertension and the Hanshin-Awaji earthquake. Lancet 345 : 1365, 1995.
PubMed
10) Nishizawa M, et al : Strict Blood Pressure Control Achieved Using an ICT-Based Home Blood Pressure Monitoring System in a Catastrophically Damaged Area After a Disaster. J Clin Hypertens (Greenwich) 19 : 26-29, 2017.
 
P.577 掲載の参考文献
1) Noble D : Modeling the heart-from genes to cells to the whole organ. Science 295 : 1678-1682, 2002.
 
2) Suga H, et al : Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 32 : 314-322, 1973.
PubMed
3) Sunagawa K, et al : Optimal arterial resistance for the maximal stroke work studied in isolated canine left ventricle. Circ Res 56 : 586-595, 1985.
PubMed
4) Suga H : Ventricular energetics. Physiol Rev 70 : 247-277, 1990.
 
5) Burkhoff D, Sagawa K : Ventricular efficiency predicted by an analytical model. Am J Physiol 250 : R1021-1027, 1986.
PubMed
6) Neubauer S : The failing heart-an engine out of fuel. N Engl J Med 356 : 1140-1151, 2007.
PubMed
7) Asanoi H, et al : Ventriculoarterial coupling in normal and failing heart in humans. Circ Res 65 : 483-493, 1989.
PubMed
8) Braunwaid E, Colucci WS : Vasodilator therapy of heart failure. Has the promissory note been paid? N Engl J Med 310 : 459-461, 1984.
 
9) Sugiura S, et al : Multi-scale simulations of cardiac electrophysiology and mechanics using the University of Tokyo heart simulator. Prog Biophys Mol Biol 110 : 380-389, 2012.
PubMed
10) Washio T, et al : Multiscale heart simulation with cooperative stochastic cross-bridge dynamics and cellular structures. Multiscale Modeling and Simulation 11 : 965-999, 2013.
 
11) Okada J, et al : Patient specific simulation of body surface ECG using the finite element method. Pacing Clin Electrophysiol 36 : 309-321, 2013.
PubMed
12) Okada J, et al : Transmural and apicobasal gradients in repolarization contribute to T-wave genesis in human surface ECG. Am J Physiol Heart Circ Physiol 301 : H200-208, 2011.
 
13) Okada JI, et al : Multi-scale, tailor-made heart simulation can predict the effect of cardiac resynchronization therapy. J Mol Cell Cardiol 108 : 17-23, 2017.
PubMed
14) Panthee N, et al : Tailor-made heart simulation predicts the effect of cardiac resynchronization therapy in a canine model of heart failure. Med Image Anal 31 : 46-62, 2016.
 
15) Okada J, et al : Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator. Sci Adv 1 : e1400142, 2015.
PubMed
P.585 掲載の参考文献
1) Cappuccio FP, et al : Sleep duration predicts cardiovascular outcomes : a systematic review and meta-analysis of prospective studies. Eur Heart J 32 : 1484-1492, 2011.
PubMed
2) Spiegel K, et al : Impact of sleep debt on metabolic and endocrine function. Lancet 354 : 1435-1439, 1999.
PubMed
3) Laugsand LE, et al : Insomnia and the risk of incident heart failure : a population study. Eur Heart J 35 : 1382-1393, 2014.
PubMed
4) King DP, et al : Positional cloning of the mouse circadian clock gene. Cell 89 : 641-653, 1997.
PubMed
5) Young ME, et al : Intrinsic diurnal variations in cardiac metabolism and contractile function. Circ Res 89 : 1199-1208, 2001.
PubMed
6) Kung TA, et al : Rapid attenuation of circadian clock gene oscillations in the rat heart following ischemia-reperfusion. J Mol Cell Cardiol 43 : 744-753, 2007.
PubMed
7) Pan A, et al : Rotating night shift work and risk of type 2 diabetes : two prospective cohort studies in women. PLoS Med 8 : e1001141, 2011.
PubMed
8) Penev PD, et al : Chronic circadian desynchronization decreases the survival of animals with cardiomyopathic heart disease. Am J Physiol 275 : H2334-2337, 1998.
PubMed
9) Martino TA, et al : Disturbed diurnal rhythm alters gene expression and exacerbates cardiovascular disease with rescue by resynchronization. Hypertension 49 : 1104-1113, 2007.
PubMed
10) Anea CB, et al : Vascular disease in mice with a dysfunctional circadian clock. Circulation 119 : 1510-1517, 2009.
PubMed
11) Doi M, et al : Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 16 : 67-74, 2010.
PubMed
12) Xie Z, et al : Smooth-muscle BMAL1 participates in blood pressure circadian rhythm regulation. J Clin Invest 125 : 324-336, 2015.
PubMed
13) Young ME, et al : Cardiomyocyte-specific BMAL1 plays critical roles in metabolism, signaling, and maintenance of contractile function of the heart. J Biol Rhythms 29 : 257-276, 2014.
 
14) Nozawa M, et al : Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther 316 : 176-181, 2006.
PubMed
15) Montaigne D, et al : Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbαantagonism : a single-centre propensity-matched cohort study and a randomised study. Lancet 391 : 59-69, 2018.
 
P.590 掲載の参考文献
1) Taylor RS, et al : Effects of exercise training for heart failure with preserved ejection fraction : a systematic review and meta-analysis of comparative studies. Int J Cardiol 162 : 6-13, 2012.
PubMed
2) Reeves GR, et al : Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial : Design and rationale. Am Heart J 185 : 130-139, 2017.
PubMed
3) Butler J, et al : Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 9 : 2016.
PubMed
4) Yamamoto K : Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med 60 : 71-76, 2017.
PubMed
5) Obokata M, et al : Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. Eur Heart J 39 : 2810-2821, 2018.
PubMed
6) Kaye D, et al : Effects of an interatrial shunt on rest and exercise hemodynamics : results of a computer simulation in heart failure. J Card Fail 20 : 212-221, 2014.
PubMed
7) Hasenfuβ G, et al : A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF) : a multicentre, open-label, single-arm, phase 1 trial. Lancet 387 : 1298-1304, 2016.
 
8) Kaye DM, et al : One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 9 : 2016.
PubMed
9) Wessler J, et al : Impact of Baseline Hemodynarnics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 11 : e004540, 2018.
PubMed
10) Shah SJ, et al : One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial : A Randomized Clinical Trial. JAMA Cardiol 3 : 968-977, 2018.
 
11) Feldman T, et al : Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure] ) : A Phase 2, Randomized, Sham-Controlled Trial. Circulation 137 : 364-375, 2018.
PubMed
12) Del Trigo M, et al : Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction : a safety and proof-of-principle cohort study. Lancet 387 : 1290-1297, 2016.
PubMed
13) Rodes-Cabau J, et al : Interatrial Shunting for Heart Failure : Early and Late Results From the Firstin-Human Experience With the V-Wave System. JACC Cardiovasc Interv 11 : 2300-2310, 2018.
 
14) Wilson JR, et al : Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation 92 : 47-53, 1995.
PubMed
P.596 掲載の参考文献
1) 佐藤広康 : 慢性心不全に対する代替療法 漢方薬による伝統的医療. Current Therapy 33 : 1215-1220, 2015.
 
2) 西田清一郎, 佐藤広康 : 木防已湯の慢性心不全治療における新しい臨床応用の可能性について. 漢方と最新治療 18 : 297-303, 2009.
 
3) Satoh H : Pharmacological effectiveness of the active phytochemicals contained in foods and herbs. J Intercult Ethnopharmacol 3 : 196-200, 2014.
PubMed
4) 佐藤広康 : 漢方薬理学 : 漢方生薬に含有する植物由来生理学的機能物質 (フィトケミカル) の薬理作用. 日薬理誌 146 : 125, 2015.
 
5) Nishida S, Satoh H : Vascular pharmacology of mokuboito (mu-fang-yi-tang) and its constituents on the smooth muscle and the endothelium in rat aorta. Evid Based Complement Alternat Med 4 : 335-341, 2007.
 
6) 佐藤広康, 西田清一郎 : シノメニンの心臓イオンチャネルと大動脈血管への薬理作用 : 漢方薬 (多成分複合薬) の加齢的特徴. 日薬理誌 146 : 126-129, 2015.
 
7) Satoh H : Electropharmacological actions of the constituents of Sinorneni Caulis et Rhizome and Mokuboi-to in guinea pig heart. Am J Chin Med 33 : 967-979, 2005.
PubMed
8) Nishida S, Satoh H : Cardiovascular pharmacology of sinomenine : the mechanical and electropharmacological actions. Drug Target Insights 2 : 97-104, 2007.
PubMed
9) Nishida S, Satoh H : In vitro pharmacological actions of sinomenine on the smooth muscle and the endothelial cell activity in rat aorta. Life Sci 79 : 1203-1206, 2006.
PubMed
10) Satoh H : Modulation of the Pacemaker Activity by Phytochemicals (Sinomenine, Tetrandrine and Magnoflorine) of Sinomeni Caulis et Rhizoma Spontaneously Beating Sino-Atrial Nodal Cells. EC Pharmacol Toxicol 6 : 429-438, 2018.
 
11) Satoh H, Nishida S : Lack of the age-dependent alteration in Mokuboito (Mu-Fang-Yi-Tang). J US-China Med Sci 9 : 1-8, 2012.
 
12) Nishida S, Satoh H : Age-related changes in the vasodilating actions to Ginkgo biloba extract and its main constituent, bilobalide, in rat aorta. Clin Chim Acta 354 : 141-146, 2005.
PubMed
13) Satoh H : Pharmacological characteristics of Kampo medicines as a mixture of constituents and ingredients. J Integr Med 11 : 11-16, 2013.
PubMed
14) 佐藤広康 : 漢方薬理学 : 補完・代替医療としての漢方方剤. 日薬理誌 140 : 54-57, 2012.
Medical*Online
P.603 掲載の参考文献
1) O'Neill WW, et al : The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock : results from the USpella Registry. J Interv Cardiol 27 : 1-11, 2014.
PubMed
2) O'Neill WW, et al : A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention : the PROTECT II study. Circulation 126 : 1717-1727, 2012.
PubMed
3) Fincke R, et al ; SHOCK Investigators : Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock : a report from the SHOCK trial registry. J Am Coll Cardiol 44 : 340-348, 2004.
PubMed
4) Arnaoutakis GJ, et al : Surgical repair of ventricular septal defect after myocardial infarction : outcomes from the Society of Thoracic Surgeons National Database. Ann Thorac Surg 94 : 436-443 ; discussion 443-444, 2012.
 
5) Jones BM, et al : Ventricular septal rupture complicating acute myocardial infarction : a contemporary review. Eur Heart J 35 : 2060-2068, 2014.
PubMed
6) La Torre MW, et al : Posterior ventricular septal defect in presence of cardiogenic shock : early implantation of the impella recover LP 5.0 as a bridge to surgery. Tex Heart Inst J 38 : 42-49, 2011.
 
7) Saku K, et al : Left Ventricular Mechanical Unloading by Total Support of Impella in Myocardial Infarction Reduces Infarct Size, Preserves Left Ventricular Function, and Prevents Subsequent Heart Failure in Dogs. Circ Heart Fail 11 : e004397, 2018.
PubMed
8) Kapur NK, et al : Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation 128 : 328-336, 2013.
PubMed
9) Flaherty MP, et al : Early Initiation of Impella in Acute Myocardial Infarction Complicated by Cardiogenic Shock Improves Survival : A Meta-Analysis. JACC Cardiovasc Interv 10 : 1805-1806, 2017.
PubMed
10) Esposito ML, et al : Left Ventricular Unloading Before Reperfusion Promotes Functional Recovery After Acute Myocardial Infarction. J Am Coll Cardiol 72 : 501-514, 2018.
PubMed
11) Kapur NK, et al : Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial Infarction. Circulation 139 : 337-346, 2019.
PubMed
P.608 掲載の参考文献
1) Hulot JS, et al : Gene therapy for the treatment of heart failure : promise postponed. Eur Heart J 37 : 1651-1658, 2016.
PubMed
2) Greenberg B : Gene therapy for heart failure. Trends Cardiovasc Med 27 : 216-222, 2017.
PubMed
3) Greenberg B, et al : Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther 23 : 313-319, 2016.
PubMed
4) Pulicherla N, et al : Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 19 : 1070-1078, 2011.
 
5) Kawase Y, et al : Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51 : 1112-1119, 2008.
 
6) Jaski BE, et al : Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 15 : 171-181, 2009.
 
7) Jessup M, et al : Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) : a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+ -ATPase in patients with advanced heart failure. Circulation 124 : 304-313, 2011.
PubMed
8) Zsebo K, et al : Long-term effects of AAVI/SERCA2a gene transfer in patients with severe heart failure : analysis of recurrent cardiovascular events and mortality. Circ Res 114 : 101-108, 2014.
 
9) Greenberg B, et al : Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure : the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2 : 84-92, 2014.
PubMed
10) Greenberg B, et al : Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2) : a randornised, multinational, double-blind, placebocontrolled, phase 2b trial. Lancet 387 : 1178-1186, 2016.
PubMed
11) Hulot JS, et al : Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure : results from the AGENT-HF randomized phase 2 trial. Eur J Heart Fail 19 : 1534-1541, 2017.
 
12) Lai NC, et al : Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110 : 330-336, 2004.
PubMed
13) Hammond HK, et al : Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure : A Randomized Clinical Trial. JAMA Cardiol 1 : 163-171, 2016.
PubMed
14) Askari AT, et al : Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362 : 697-703, 2003.
PubMed
15) Chung ES, et al : Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients : the STOP-HF randomized Phase II trial. Eur Heart J 36 : 2228-2238, 2015.
 
P.616 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
2) Packer M, et al : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med 334 : 1349-1355, 1996.
 
3) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999.
 
4) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
5) Dungen HD, et al : Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure : the CIBIS-ELD trial. Eur J Heart Fail 13 : 670-680, 2011.
PubMed
6) Hori M, et al : Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure : results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels 29 : 238-247, 2014.
PubMed
7) Tsutsui H, et al ; on behalf of CIBIS-J Investigators : Tolerability, efficacy, and safety of bisoprolol vs. carvedilol in Japanese patients with heart failure and reduced ejection fraction : the CIBIS-J trial. Circ J (in press).
 
P.622 掲載の参考文献
1) Kannel WB, et al : Heart rate and cardiovascular mortality : the Framingham Study. Am Heart J 113 : 1489-1494, 1987.
PubMed
2) Panza JA, et al : Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol 20 : 1092-1098, 1992.
PubMed
3) Ingwall JS, Weiss RG : Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95 : 135-145, 2004.
PubMed
4) Giannoglou GD, et al : Elevated heart rate and atherosclerosis : an overview of the pathogenetic mechanisms. Int J Cardiol 126 : 302-312, 2008.
PubMed
5) Heidland UE, Strauer BE : Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104 : 1477-1482, 2001,
PubMed
6) Colucci WS, et al : Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure : US Carvedilol Heart Failure Study Group. Circulation 94 : 2800-2806, 1996.
 
7) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999.
 
8) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
PubMed
9) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
 
10) Writing Committee Members ; Yancy CW, et al : 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure : An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134 : e282-293, 2016.
 
11) 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
12) McAlister FA, et al : Meta-analysis : beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 : 784-794, 2009.
PubMed
13) Ide T, et al : Ivabradine for the treatment of cardiovascular diseases. Circ J. 83 : 252-260, 2019.
PubMed
14) Swedberg K, et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebocontrolled study. Lancet 376 : 875-885, 2010.
PubMed
15) Borer JS, et al : Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure : the SHIFT Study. Eur Heart J 33 : 2813-2820, 2012.
PubMed
16) Tardif JC, et al : Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function : results from the SHIFT echocardiography substudy. Eur Heart J 32 : 2507-2515, 2011.
PubMed
17) Ekman I, et al : Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure : results from the SHIFT study. Eur Heart J 32 : 2395-2404, 2011.
PubMed
18) Bohm M, et al : Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure : analysis from the SHIFT study. Clin Res Cardiol 102 : 11-22, 2013.
PubMed
19) Swedberg K, et al : Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure : is there an influence of beta-blocker dose? : findings from the SHIFT (Systolic Heart failure treatment with the I (f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 59 : 1938-1945, 2012.
 
20) Tavazzi L, et al : Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease : an efficacy and safety analysis of SHIFT study. Int J Cardiol 170 : 182-188, 2013.
PubMed
21) Tavazzi L, et al : Efficacy and safety of ivabradine in chronic heart failure across the age spectrum : insights from the SHIFT study. Eur J Heart Fail 15 : 1296-1303, 2013.
PubMed
22) Komajda M, et al : Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail 16 : 810-816, 2014.
PubMed
23) Bocchi EA, et al : Effect of Combining Ivabradine and β-Blockers : Focus on the Use of Carvedilol in the SHIFT Population. Cardiology 131 : 218-224, 2015.
 
24) Bohm M, et al : Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). Am J Cardiol 116 : 1890-1897, 2015.
PubMed
25) Komajda M, et al : Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail 15 : 79-84, 2013.
PubMed
26) Bohm M, et al : Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine : findings frorn SHIFT. Eur J Heart Fail 20 : 373-381, 2018.
 
27) Komajda M, et al : Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure : a post-hoc analysis of SHIFT. Eur J Heart Fail 18 : 1182-1189, 2016.
PubMed
28) Borer JS, et al : Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure : the SHIFT Study. Eur Heart J 33 : 2813-2820, 2012.
PubMed
29) Rogers JK, et al : Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients. Curr Med Res Opin 31 : 1903-1909, 2015.
PubMed
30) Borer JS, et al : Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 113 : 497-503, 2014.
PubMed
31) Borer JS, et al : Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology 136 : 138-144, 2017.
PubMed
32) Komajda M, et al : Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes : an analysis from the SHIFT trial. Eur J Heart Fail 17 : 1294-1301, 2015.
PubMed
33) Voors AA, et al : The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure : an analysis from SHIFT. Eur J Heart Fail 16 : 426-434, 2014.
PubMed
34) Reil JC, et al : Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail 15 : 1044-1052, 2013.
PubMed
35) Tsutsui H, et al ; on behalf of the study investigators : Heart Rate Control With If Inhibitor, ivabradine, in Japanese patients with chronic heart failure-A randomized, double-blind, placebo-controlled phase II study. Circ J 80 : 668-676, 2016.
 
36) Tsutsui H, et al : Efficacy and safety of Ivabradine in Japanese patients with chronic heart : J-SHIFT Study. The 83rd Annual Scientific Meeting of the Japanese Circulation Society (abstract).
 

書評

最近チェックした商品履歴

Loading...